Primary biliary cirrhosis

Hepatology
50, 291-308
DOI: 10.1002/hep.22906

Citation Report

#	Article	IF	Citations
1	Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study. Hepatology, 2009, 50, 1884-1892.	7.3	114
2	Toward the molecular dissection of primary biliary cirrhosis. Hepatology, 2009, 50, 1347-1350.	7.3	10
3	Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines. Journal of Hepatology, 2009, 51, 1084-1085.	3.7	15
4	Ursodeoxycholic acid in primary biliary cirrhosis: Reply. Journal of Hepatology, 2009, 51, 1085-1086.	3.7	28
8	Liver disease in women: Examining prevalence and complications. Gastrointestinal Nursing, 2010, 8, 30-37.	0.1	2
9	Stigma and Liver Disease. Illness Crisis and Loss, 2010, 18, 229-255.	0.7	15
10	Latest and Emerging Therapies for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Current Gastroenterology Reports, 2010, 12, 13-22.	2.5	24
11	Autoantibodies as Prognostic Markers in Autoimmune Liver Disease. Digestive Diseases and Sciences, 2010, 55, 2144-2161.	2.3	72
12	Methotrexate in Patients with Primary Biliary Cirrhosis Who Respond Incompletely to Treatment With Ursodeoxycholic Acid. Digestive Diseases and Sciences, 2010, 55, 3207-3217.	2.3	27
13	Triple therapy for patients with primary biliary cirrhosis with progressive disease despite ursodeoxycholic acid: Another step forward. Gastroenterologie Clinique Et Biologique, 2010, 34, 239-241.	0.9	1
14	Extrahepatic conditions associated with primary biliary cirrhosis. Hepatology, 2010, 51, 713-713.	7.3	1
15	Diagnosis and management of primary sclerosing cholangitis. Hepatology, 2010, 51, 660-678.	7.3	1,048
16	Biliary physiology and disease: Reflections of a physician-scientist. Hepatology, 2010, 51, 1095-1106.	7.3	26
18	The specificity of fatigue in primary biliary cirrhosis: Evaluation of a large clinic practice. Hepatology, 2010, 52, 562-570.	7.3	46
19	High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology, 2010, 52, 472-479.	7.3	267
20	Non-neoplastic diseases of the intra- and extrahepatic bile ducts. Diagnostic Histopathology, 2010, 16, 380-387.	0.4	0
21	Primary biliary cirrhosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 647-654.	2.4	32
22	Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 655-657.	21.4	205

#	Article	IF	Citations
23	Pharmacotherapy of cholestatic liver diseases. Journal of Digestive Diseases, 2010, 11, 119-125.	1.5	18
25	Validation of Coding Algorithms for the Identification of Patients with Primary Biliary Cirrhosis Using Administrative Data. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 175-182.	1.7	17
26	Hepatocyte Death: A Clear and Present Danger. Physiological Reviews, 2010, 90, 1165-1194.	28.8	399
27	Cholestatic Pruritus: Colesevelam. Hospital Pharmacy, 2010, 45, 914-915.	1.0	0
28	PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2010, 105, 125-131.	0.4	69
29	Cholestatic Pruritus: Sertraline (Adults). Hospital Pharmacy, 2010, 45, 768-770.	1.0	0
30	Treatment options for primary sclerosing cholangitis. Expert Review of Gastroenterology and Hepatology, 2010, 4, 473-488.	3.0	16
31	Innovative Management of Pruritus. Dermatologic Clinics, 2010, 28, 467-478.	1.7	26
32	Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. Digestive and Liver Disease, 2010, 42, 911-912.	0.9	22
33	Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?. Translational Research, 2010, 155, 120-122.	5.0	2
34	Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches. Gastroenterology, 2010, 139, 1481-1496.	1.3	222
35	A2BP1 as a novel susceptible gene for primary biliary cirrhosis in Japanese patients. Human Immunology, 2010, 71, 520-524.	2.4	18
36	Primary biliary cirrhosis: A 2010 update. Journal of Hepatology, 2010, 52, 745-758.	3.7	251
37	Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers. Journal of Hepatology, 2010, 53, 307-312.	3.7	104
38	Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. Journal of Hepatology, 2010, 53, 537-541.	3.7	38
39	MARS: The ultimate warrior against pruritus of cholestasis?. Journal of Hepatology, 2010, 53, 228-229.	3.7	2
40	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 436-442.	6.5	123
43	Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. Expert Opinion on Pharmacotherapy, 2010, 11, 387-392.	1.8	14

#	Article	IF	Citations
44	Primary sclerosing cholangitis: overview and update. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 611-619.	17.8	49
47	Model for End-Stage Liver Disease Score Predicts Outcome in Cirrhotic Patients During Pregnancy. Clinical Gastroenterology and Hepatology, 2011, 9, 694-699.	4.4	106
48	Prevalence of Primary Biliary Cirrhosisâ€“Autoimmune Hepatitis Overlap Syndrome. Clinical Gastroenterology and Hepatology, 2011, 9, 609-612.	4.4	52
49	The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 29-33.	1.5	19
50	Pathophysiology and current management of pruritus in liver disease. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 89-97.	1.5	90
51	Disease-specific autoantibodies in primary biliary cirrhosis. Clinica Chimica Acta, 2011, 412, 502-512.	1.1	86
52	Diagnostic criteria for autoimmune hepatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 665-671.	2.4	22
53	Diagnosis of primary biliary cirrhosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 701-712.	2.4	29
54	A possible involvement of p62/sequestosomeâ€1 in the process of biliary epithelial autophagy and senescence in primary biliary cirrhosis. Liver International, 2012, 32, 487-499.	3.9	45
55	Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. Journal of Hepatology, 2011, 54, 340-347.	3.7	85
56	Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. Journal of Hepatology, 2011, 54, 374-385.	3.7	470
57	Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. Journal of Hepatology, 2011, 55, 1361-1367.	3.7	353
58	A major step towards effective treatment evaluation in primary biliary cirrhosis. Journal of Hepatology, 2011, 55, 1178-1180.	3.7	12
59	The Itch of Liver Disease. Seminars in Cutaneous Medicine and Surgery, 2011, 30, 93-98.	1.6	42
60	Primary Biliary Cirrhosis. Gastroenterology Clinics of North America, 2011, 40, 373-386.	2.2	18
61	Urinary bile acid sulfate levels in patients with primary biliary cirrhosis. Hepatology Research, 2011, 41, 358-363.	3.4	10
62	Detection of Dâ€3â€phosphoglycerate dehydrogenase autoantibodies in patients with autoimmune hepatitis: Clinical significance evaluation. Hepatology Research, 2011, 41, 867-876.	3.4	5
63	Primary biliary cirrhosis â€“ Autoimmune hepatitis overlap syndrome: A rationale for corticosteroids use based on a nationâ€wide retrospective study in Japan. Hepatology Research, 2011, 41, 877-886.	3.4	40

#	Article	IF	Citations
64	Primary biliary cirrhosis. Lancet, The, 2011, 377, 1600-1609.	13.7	294
65	The diagnosis and treatment of primary biliary cirrhosis. The Korean Journal of Hepatology, 2011, 17, 173.	1.5	19
66	Clinical significance of anti-mitochondrial antibodies in a patient with chronic graft-versus-host disease following hematopoietic stem cell transplantation. The Korean Journal of Hematology, 2011, 46, 200.	0.7	4
67	Varices in Early Histological Stage Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2011, 45, e66-e71.	2.2	40
68	Parenteral Bisphosphonates for Osteoporosis in Patients With Primary Biliary Cirrhosis. American Journal of Therapeutics, 2011, 18, 375-381.	0.9	16
70	Genetic association of Fc receptorâ€like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. Tissue Antigens, 2011, 77, 239-243.	1.0	21
71	Replicated association of 17q12â€21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. Tissue Antigens, 2011, 78, 65-68.	1.0	31
72	No more pilots, a phase III trial of fibrates in primary biliary cirrhosis is long overdue!. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1345-1346.	2.8	7
73	Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Alimentary Pharmacology and Therapeutics, 2011, 33, 235-242.	3.7	153
74	Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clinical and Experimental Immunology, 2011, 163, 147-156.	2.6	42
75	A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver International, 2011, 31, 361-368.	3.9	62
76	The impact of biopsychosocial factors on quality of life: Women with primary biliary cirrhosis on waiting list and post liver transplantation. British Journal of Health Psychology, 2011, 16, 502-527.	3.5	15
77	Development of Hepatocellular Carcinoma in Autoimmune Hepatitis Patients: A Case Series. Digestive Diseases and Sciences, 2011, 56, 578-585.	2.3	66
78	Performance Parameters of the Conventional Serological Markers for Autoimmune Hepatitis. Digestive Diseases and Sciences, 2011, 56, 545-554.	2.3	70
79	Prognostic Factors and Survival Analysis of Antimitochondrial Antibody-Positive Primary Biliary Cirrhosis in Chinese Patients. Digestive Diseases and Sciences, 2011, 56, 2750-2757.	2.3	11
80	Hepatobiliary Complications of Inflammatory Bowel Disease. Current Gastroenterology Reports, 2011, 13, 495-505.	2.5	16
81	Autoimmune liver disease - are there spectra that we do not know?. Comparative Hepatology, 2011, 10, 9.	0.9	11
82	Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. Immunity and Ageing, 2011, 8, 12.	4.2	25

#	Article	IF	Citations
83	Human leukocyte antigen in primary biliary cirrhosis: An old story now reviving. Hepatology, 2011, 54, 714-723.	7.3	74
84	Primary biliary cirrhosis/autoimmune hepatitis overlap syndrome developing in a patient with systemic lupus erythematosus: a case report and review of the literature. Lupus, 2011, 20, 108-111.	1.6	13
85	Multiple Autoimmune Propensity and B-Non-Hodgkin Lymphoma: Cause or Effect?. Autoimmune Diseases, 2011, 2011, 1-5.	0.6	1
86	Primary Biliary Cirrhosis: Family Stories. Autoimmune Diseases, 2011, 2011, 1-11.	0.6	34
87	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human Molecular Genetics, 2012, 21, 5209-5221.	2.9	139
88	Sex Differences Associated with Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	37
89	The use of plasmapheresis in managing primary biliary cirrhosis presenting with profound hypercholesterolaemia. British Journal of Diabetes and Vascular Disease, 2012, 12, 156-158.	0.6	2
90	Liver immunology. , 2012, , 153-165.e2.		0
91	Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes and Immunity, 2012, 13, 328-335.	4.1	78
92	Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature. Tuberculosis Research and Treatment, 2012, 2012, 1-10.	0.6	2
93	Rheumatoid Arthritis and Primary Biliary Cirrhosis: Cause, Consequence, or Coincidence?. Arthritis, 2012, 2012, 1-7.	2.0	21
94	Twelve-Year-Old Girl with Primary Biliary Cirrhosis. Case Reports in Pediatrics, 2012, 2012, 1-3.	0.4	6
95	Natural history and management of primary biliary cirrhosis. Hepatic Medicine: Evidence and Research, 2012, 4, 61.	2.5	11
96	Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain, 2012, 135, 1767-1777.	7.6	95
97	Clinical Guideline of Primary Biliary Cirrhosis 2012 The Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Acta Hepatologica Japonica, 2012, 53, 633-686.	0.1	6
98	The epidemiology and natural history of primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 824-830.	1.6	61
99	The Impact of Race/Ethnicity on the Clinical Epidemiology of Autoimmune Hepatitis. Journal of Clinical Gastroenterology, 2012, 46, 155-161.	2.2	61
100	Chlorambucil for patients with primary biliary cirrhosis. The Cochrane Library, 2012, , CD008714.	2.8	4

#	Article	IF	Citations
101	A Case of IgG4-related Sclerosing Cholangitis Overlapped with Primary Biliary Cirrhosis. Internal Medicine, 2012, 51, 1695-1699.	0.7	11
104	Primary biliary cirrhosis and cancer risk: A systematic review and meta-analysis. Hepatology, 2012, 56, 1409-1417.	7.3	94
105	The immunopathology of liver granulomas in primary biliary cirrhosis. Journal of Autoimmunity, 2012, 39, 216-221.	6.5	48
106	Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies. Autoimmunity Highlights, 2012, 3, 105-112.	3.9	7
107	Popular and unpopular infectious agents linked to primary biliary cirrhosis. Autoimmunity Highlights, 2012, 3, 95-104.	3.9	4
108	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. Autoimmunity Highlights, 2012, 3, 127-132.	3.9	4
109	Prevalence and Mechanisms of Malnutrition in Patients With Advanced Liver Disease, and Nutrition Management Strategies. Clinical Gastroenterology and Hepatology, 2012, 10, 117-125.	4.4	270
110	Pruritus in Chronic Cholestatic Liver Disease. Clinics in Liver Disease, 2012, 16, 331-346.	2.1	58
111	Liver Disease in Pregnancy. Clinics in Liver Disease, 2012, 16, 247-269.	2.1	18
112	ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study. Journal of Ultrasound, 2012, 15, 226-231.	1.3	23
113	Levercirrose. Bijblijven (Amsterdam, Netherlands), 2012, 28, 43-52.	0.0	0
114	Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver International, 2012, 32, 790-795.	3.9	62
115	Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. Journal of Hepatology, 2012, 57, 133-140.	3.7	97
116	Cholestasis-induced pruritus treated with ultraviolet B phototherapy: An observational case series study. Journal of Hepatology, 2012, 57, 637-641.	3.7	50
117	Primary biliary cirrhosis and SjÃ¶grenâ€™s syndrome: Autoimmune epithelitis. Journal of Autoimmunity, 2012, 39, 34-42.	6.5	118
118	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterology, 2012, 12, 92.	2.0	24
119	The Overlap Syndromes of Autoimmune Hepatitis. Digestive Diseases and Sciences, 2012, 58, 326-43.	2.3	62
120	Answers to Multiple Choice Questions. Journal of Clinical and Experimental Hepatology, 2012, 2, 401-406.	0.9	0

#	Article	IF	Citations
121	Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population. American Journal of Human Genetics, 2012, 91, 721-728.	6.2	251
122	Urinary tract infection as a risk factor for autoimmune liver disease: From bench to bedside. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 110-121.	1.5	42
123	Liver biopsy is a superior diagnostic method in some patients showing the typical laboratory features of autoimmune hepatitis. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 185-188.	1.5	6
124	What Is New in Primary Biliary Cirrhosis?. Digestive Diseases, 2012, 30, 20-31.	1.9	15
125	The Immunophysiology and Apoptosis of Biliary Epithelial Cells: Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinical Reviews in Allergy and Immunology, 2012, 43, 230-241.	6.5	28
126	Complete spectrum of AMA-M2 positive liver disease in north India. Hepatology International, 2012, 6, 790-795.	4.2	3
127	Current pharmacotherapy for cholestatic liver disease. Expert Opinion on Pharmacotherapy, 2012, 13, 2473-2484.	1.8	26
128	Primary biliary cirrhosis and bile acids. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, S13-S20.	1.5	25
129	Granulomatous Liver Disease. Clinics in Liver Disease, 2012, 16, 387-396.	2.1	28
130	Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology, 2012, 11, 7-14.	1.5	36
131	Overlap Syndromes. , 2012, , 782-789.		0
132	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology, 2012, 55, 1495-1506.	7.3	35
133	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology, 2012, 56, 198-208.	7.3	277
134	Overcoming a â€œProbableâ€•Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature. Clinical Reviews in Allergy and Immunology, 2012, 42, 288-297.	6.5	70
135	Autoimmunity and Environment: Am I at risk?. Clinical Reviews in Allergy and Immunology, 2012, 42, 199-212.	6.5	60
136	Immunological diseases of the pancreatico-hepatobiliary system: update on etiopathogenesis and cross-sectional imaging findings. Abdominal Imaging, 2012, 37, 261-274.	2.0	6
137	â€˜Outâ€patientâ€™ albumin dialysis for cholestatic patients with intractable pruritus. Alimentary Pharmacology and Therapeutics, 2012, 35, 696-704.	3.7	42
138	Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. Journal of Digestive Diseases, 2012, 13, 219-224.	1.5	51

#	Article	IF	Citations
139	Different patterns of decompensation in patients with alcoholic vs. nonâ€alcoholic liver cirrhosis. Alimentary Pharmacology and Therapeutics, 2012, 35, 1443-1450.	3.7	27
140	Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus. British Journal of Clinical Pharmacology, 2012, 73, 826-827.	2.4	16
141	Pathogenesis and management of pruritus in cholestatic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1150-1158.	2.8	50
142	Cytotoxic Tâ€lymphocyte associated antigenâ€4 gene polymorphisms and primary biliary cirrhosis: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1159-1166.	2.8	18
143	Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology, 2012, 55, 506-511.	7.3	73
144	Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology, 2012, 55, 512-521.	7.3	130
145	Vitamin D Deficiency in Patients with Chronic Liver Disease and Cirrhosis. Current Gastroenterology Reports, 2012, 14, 67-73.	2.5	55
146	Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis. Autoimmunity Highlights, 2013, 4, 1-9.	3.9	16
147	AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations. Hepatology, 2013, 58, 2142-2152.	7.3	54
148	Comparative proteomics study on liver mitochondria of primary biliary cirrhosis mouse model. BMC Gastroenterology, 2013, 13, 64.	2.0	6
149	Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatology International, 2013, 7, 775-784.	4.2	22
150	Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. Journal of Gastroenterology, 2013, 48, 1160-1170.	5.1	26
151	Review article: the management of autoimmune hepatitis beyond consensus guidelines. Alimentary Pharmacology and Therapeutics, 2013, 38, 343-364.	3.7	50
152	Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis. Clinical and Experimental Nephrology, 2013, 17, 405-410.	1.6	7
153	Liver transplantation and autoimmune liver diseases. Liver Transplantation, 2013, 19, 1065-1077.	2.4	83
154	A pilot study of umbilical cordâ€derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 85-92.	2.8	153
155	Apotopes and innate immune system: Novel players in the primary biliary cirrhosis scenario. Digestive and Liver Disease, 2013, 45, 630-636.	0.9	24
156	Not All PBC Is the Same!. Gastroenterology, 2013, 144, 494-497.	1.3	5

#	Article	IF	Citations
157	Primary biliary cirrhosis: Is there still a place for histological evaluation?. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 556-558.	1.5	5
158	Analysis of altered <scp>microRNA</scp> expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 543-550.	2.8	38
160	Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 572-585.	1.5	54
161	Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Alimentary Pharmacology and Therapeutics, 2013, 38, 794-803.	3.7	14
162	High Levels of FCÎ³R3A and PRF1 Expression in Peripheral Blood Mononuclear Cells from Patients with Primary Biliary Cirrhosis. Digestive Diseases and Sciences, 2013, 58, 458-464.	2.3	2
163	Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29â€year cohort study. Alimentary Pharmacology and Therapeutics, 2013, 38, 1354-1364.	3.7	32
164	The dynamic biliary epithelia: Molecules, pathways, and disease. Journal of Hepatology, 2013, 58, 575-582.	3.7	130
166	Association analysis of toll-like receptor 4 polymorphisms in Japanese primary biliary cirrhosis. Human Immunology, 2013, 74, 219-222.	2.4	6
167	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. Journal of Autoimmunity, 2013, 46, 81-87.	6.5	64
168	A validated clinical tool for the prediction of varices in PBC: The Newcastle Varices in PBC Score. Journal of Hepatology, 2013, 59, 327-335.	3.7	31
169	Liver Transplant for Cholestatic Liver Diseases. Clinics in Liver Disease, 2013, 17, 345-359.	2.1	20
170	Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: Whatâ€™s New?. Current Infectious Disease Reports, 2013, 15, 14-24.	3.0	22
171	Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis. Liver International, 2013, 33, 312-320.	3.9	58
172	Î²1 integrin is a long-sought sensor for tauroursodeoxycholic acid. Hepatology, 2013, 57, 867-869.	7.3	8
173	Gutâ€“liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Review of Gastroenterology and Hepatology, 2013, 7, 253-261.	3.0	39
174	Cholestatic Liver Disease Overlap Syndromes. Clinics in Liver Disease, 2013, 17, 243-253.	2.1	8
175	Primary Biliary Cirrhosis. Clinics in Liver Disease, 2013, 17, 229-242.	2.1	27
176	The Immunobiology and Pathophysiology of Primary Biliary Cirrhosis. Annual Review of Pathology: Mechanisms of Disease, 2013, 8, 303-330.	22.4	264

#	Article	IF	Citations
177	Human intrahepatic biliary epithelial cells engulf blebs from their apoptotic peers. Clinical and Experimental Immunology, 2013, 172, 95-103.	2.6	25
178	B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid. American Journal of Gastroenterology, 2013, 108, 933-941.	0.4	102
179	A case of primary biliary cirrhosis and autoimmune hepatitis overlap showing acute presentation and transient seropositivity for immunoglobulin G and anti-nuclear antibody. Clinical Journal of Gastroenterology, 2013, 6, 465-469.	0.8	0
180	A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab. Case Reports in Gastroenterology, 2013, 7, 195-201.	0.6	14
181	Mouse model of primary biliary cirrhosis with progressive fibrosis: Are we there yet?. Hepatology, 2013, 57, 429-431.	7.3	10
182	Treatment of autoimmune liver disease: current and future therapeutic options. Therapeutic Advances in Chronic Disease, 2013, 4, 119-141.	2.5	40
183	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes and Immunity, 2013, 14, 179-186.	4.1	52
184	Red blood cell distribution width is a potential prognostic index for liver disease. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1403-8.	2.3	95
185	Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary Cirrhosis. Clinical Pharmacology in Drug Development, 2013, 2, 231-236.	1.6	5
186	Anti-mitochondrial antibody: Potential marker of myositis with chronic clinical course, muscle atrophy, cardiac involvement and granulomatous inflammation in muscle biopsy. Clinical and Experimental Neuroimmunology, 2013, 4, 18-18.	1.0	0
187	Tired of Being Tired. Journal of Women's Health, 2013, 22, 289-290.	3.3	0
188	Keratin 19 demonstration of canal of hering loss in primary biliary cirrhosis: â€œMinimal Change PBCâ€?. Hepatology, 2013, 57, 700-707.	7.3	34
189	Primary Biliary Cirrhosis is More Severe in Overweight Patients. Journal of Clinical Gastroenterology, 2013, 47, e28-e32.	2.2	38
191	Connective tissue diseases in primary biliary cirrhosis: A population-based cohort study. World Journal of Gastroenterology, 2013, 19, 5131.	3.3	58
192	Distinct MicroRNAs Expression Profile in Primary Biliary Cirrhosis and Evaluation of miR 505-3p and miR197-3p as Novel Biomarkers. PLoS ONE, 2013, 8, e66086.	2.5	77
193	Hepatocellular carcinoma that arose from primary SjÃ¶grenâ€™s syndrome. Annals of Hepatology, 2013, 12, 824-829.	1.5	3
194	Serum MicroRNAs as Potential Biomarkers of Primary Biliary Cirrhosis. PLoS ONE, 2014, 9, e111424.	2.5	63
196	Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver. Experimental and Therapeutic Medicine, 2014, 8, 759-762.	1.8	17

#	Article	IF	Citations
197	Predicting outcome in primary biliary cirrhosis. Annals of Hepatology, 2014, 13, 316-326.	1.5	41
198	Autoimmune liver disorders and small-vessel vasculitis: four case reports and review of the literature. Annals of Hepatology, 2014, 13, 136-141.	1.5	11
199	Guidelines for the management of primary biliary cirrhosis. Hepatology Research, 2014, 44, 71-90.	3.4	93
200	Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Opinion on Orphan Drugs, 2014, 2, 1351-1358.	0.8	3
201	Shear Wave Elastography for Liver Stiffness Measurement in Clinical Sonographic Examinations. Journal of Ultrasound in Medicine, 2014, 33, 437-447.	1.7	85
202	The Association between Bile Salt Export Pump Single-Nucleotide Polymorphisms and Primary Biliary Cirrhosis Susceptibility and Ursodeoxycholic Acid Response. Disease Markers, 2014, 2014, 1-6.	1.3	4
203	Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomedical Reports, 2014, 2, 633-636.	2.0	89
204	Pathologies hÃ©patiques. , 2014, , 111-139.		0
205	STAT4Gene Polymorphisms Are Associated with Susceptibility and ANA Status in Primary Biliary Cirrhosis. Disease Markers, 2014, 2014, 1-8.	1.3	15
206	AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. Journal of Hepatology, 2014, 61, 1443-1445.	3.7	32
207	Changing epidemiology and natural history of primary biliary cirrhosis. Clinical Liver Disease, 2014, 3, 12-14.	2.1	3
208	Autophagy â€“ another piece of the puzzle towards understanding primary biliary cirrhosis?. Liver International, 2014, 34, 481-483.	3.9	7
209	Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology, 2014, 60, 1708-1716.	7.3	67
210	Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?. Clinical Liver Disease, 2014, 3, 29-33.	2.1	9
211	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	1.3	365
212	Overlap syndrome: A real syndrome?. Clinical Liver Disease, 2014, 3, 43-47.	2.1	8
213	Editorial for â€˜Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosisâ€™. Liver International, 2014, 34, 328-329.	3.9	1
214	Polymorphisms in the vitamin <scp>D</scp> receptor gene and risk of primary biliary cirrhosis: A metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 706-715.	2.8	14

#	Article	IF	Citations
215	Evaluation of nail fold capillaroscopy findings in patients with primary biliary cirrhosis. Hepatology Research, 2014, 44, E129-36.	3.4	6
216	Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 282-301.	3.7	75
217	Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis. Liver International, 2014, 34, 220-226.	3.9	16
218	Advances in Pathogenesis and Management of Pruritus in Cholestasis. Digestive Diseases, 2014, 32, 637-645.	1.9	58
219	Evidence-Based Treatment of Primary Biliary Cirrhosis. Digestive Diseases, 2014, 32, 626-630.	1.9	5
220	Diagnosis and management of primary biliary cirrhosis. Expert Review of Clinical Immunology, 2014, 10, 1667-1678.	3.0	20
221	Monitoring and Care. , 2014, , 478-493.		0
222	Fibrate treatment for primary biliary cirrhosis. Current Opinion in Gastroenterology, 2014, 30, 279-286.	2.3	36
223	Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 532-537.	1.6	25
224	Primary biliary cirrhosis in 2014. Current Opinion in Gastroenterology, 2014, 30, 245-252.	2.3	24
225	Treatment of primary biliary cirrhosis. Expert Opinion on Orphan Drugs, 2014, 2, 11-25.	0.8	0
226	The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases. Medical Molecular Morphology, 2014, 47, 162-168.	1.0	12
227	Pathogenesis of Bile Duct Lesions in Primary Biliary Cirrhosis. , 2014, , 293-303.		1
228	The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1533-42.	2.3	47
229	Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. Pharmaceuticals, 2014, 7, 18-28.	3.8	1
230	Primary biliary cirrhosisâ€“autoimmune hepatitis overlap syndrome: Simplified criteria may be effective in the diagnosis in <scp>C</scp>hinese patients. Journal of Digestive Diseases, 2014, 15, 660-668.	1.5	14
231	Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver International, 2014, 34, 197-203.	3.9	94
232	Progressive multifocal leukoencephalopathy in a patient with pre-clinical primary biliary cirrhosis. Clinical Neurology and Neurosurgery, 2014, 123, 45-49.	1.4	6

#	Article	IF	Citations
233	Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis: A preliminary study. Clinical Radiology, 2014, 69, 836-840.	1.1	25
234	Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 869-892.	3.8	82
235	Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. Journal of Gastroenterology, 2014, 49, 332-342.	5.1	21
236	Concurrent autoimmune pancreatitis and primary Biliary cirrhosis: a rare case report and literature review. BMC Gastroenterology, 2014, 14, 10.	2.0	5
237	Aquaporin-1 is associated with arterial capillary proliferation and hepatic sinusoidal transformation contributing to portal hypertension in primary biliary cirrhosis. Medical Molecular Morphology, 2014, 47, 90-99.	1.0	3
238	Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology, 2014, 60, 931-940.	7.3	99
239	Recurrence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis after transplantation. Clinical Liver Disease, 2014, 3, 90-92.	2.1	2
240	Cholestatic Phenotypes of Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2014, 12, 1430-1438.	4.4	55
241	Factors Associated With Response to Therapy and Outcome ofÂPatients With Primary Biliary Cirrhosis With Features ofÂAutoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2014, 12, 863-869.	4.4	64
242	Bile acids reach out to the spinal cord: New insights to the pathogenesis of itch and analgesia in cholestatic liver disease. Hepatology, 2014, 59, 1638-1641.	7.3	18
243	New therapeutics in primary biliary cirrhosis: will there ever be light?. Liver International, 2014, 34, 167-170.	3.9	8
244	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. Histopathology, 2014, 65, 174-186.	2.9	20
245	Allogeneic Bone Marrow Mesenchymal Stem Cell Transplantation in Patients with UDCA-Resistant Primary Biliary Cirrhosis. Stem Cells and Development, 2014, 23, 2482-2489.	2.1	69
246	Autoantibodies in pre-clinical autoimmune disease. Clinica Chimica Acta, 2014, 437, 14-18.	1.1	37
247	Immunologic derangement preceding clinical autoimmunity. Lupus, 2014, 23, 1305-1308.	1.6	4
248	Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. Journal of Gastroenterology, 2014, 49, 1414-1420.	5.1	35
249	Gene expression profiles of peripheral blood mononuclear cells in primary biliary cirrhosis. Clinical and Experimental Medicine, 2014, 14, 409-416.	3.6	7
250	The diagnosis of primary biliary cirrhosis. Autoimmunity Reviews, 2014, 13, 441-444.	5.8	133

#	Article	IF	Citations
251	Extrahepatic Platelet-Derived Growth Factor-Î², Delivered by Platelets, Promotes Activation of Hepatic Stellate Cells and Biliary Fibrosis in Mice. Gastroenterology, 2014, 147, 1378-1392.	1.3	127
252	Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice. Journal of Hepatology, 2014, 60, 160-166.	3.7	44
253	Good Maternal and Fetal Outcomes for Pregnant Women WithÂPrimary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1179-1185.e1.	4.4	56
255	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. Journal of Hepatology, 2014, 60, 1249-1258.	3.7	113
256	Reduced Coffee Consumption Among Individuals With Primary Sclerosing Cholangitis but Not Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1562-1568.	4.4	38
257	Increased Risk of Hepatobiliary Cancers After Hospitalization for Autoimmune Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 1038-1045.e7.	4.4	51
258	Role of liver biopsy in autoimmune liver disease. Diagnostic Histopathology, 2014, 20, 109-118.	0.4	12
259	Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2RÎ±â^'/â^' mice. Journal of Autoimmunity, 2014, 51, 99-108.	6.5	62
260	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis, 2014, 232, 99-109.	0.8	113
261	Pregnancy with Portal Hypertension. Journal of Clinical and Experimental Hepatology, 2014, 4, 163-171.	0.9	58
262	Primary biliary cirrhosis in adults. Expert Review of Gastroenterology and Hepatology, 2014, 8, 427-433.	3.0	31
263	Pruritus in cholestasis: Facts and fiction. Hepatology, 2014, 60, 399-407.	7.3	179
264	Pregnancy in women with primary biliary cirrhosis. Autoimmunity Reviews, 2014, 13, 931-935.	5.8	41
265	Autoimmunity: From black water fever to regulatory function. Journal of Autoimmunity, 2014, 48-49, 1-9.	6.5	11
267	Overlap of IgG4-related Sclerosing Cholangitis and Primary Biliary Cirrhosis. Internal Medicine, 2014, 53, 1429-1433.	0.7	12
268	Interleukin-33 Promotes Disease Progression in Patients with Primary Biliary Cirrhosis. Tohoku Journal of Experimental Medicine, 2014, 234, 255-261.	1.2	17
269	Osteoporosis and FRAX risk in patients with liver cirrhosis. Revista MÃ©dica Del Hospital General De MÃ©xico, 2014, 77, 173-178.	0.0	2
270	Genome-Wide Association Studies in Primary Biliary Cirrhosis. Seminars in Liver Disease, 2015, 35, 392-401.	3.6	59

#	Article	IF	Citations
271	Anti-mitochondrial M2 antibody-positive autoimmune hepatitis. Experimental and Therapeutic Medicine, 2015, 10, 1419-1422.	1.8	15
272	Drug treatment of pruritus in liver diseases. Clinical Medicine, 2015, 15, 351-357.	1.9	38
273	Itch and liver: management in primary care. British Journal of General Practice, 2015, 65, e418-e420.	1.4	9
274	Increased mean platelet volume is related to histologic severity of primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2015, 27, 1382-1385.	1.6	19
275	Cancer and scleroderma. Current Opinion in Rheumatology, 2015, 27, 563-570.	4.3	68
277	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Hepatology, 2015, 62, 1620-1622.	7.3	125
278	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	5.6	114
279	A case of symptomatic primary biliary cirrhosis complicated by BehÃ§et' s disease which emerged with joint swelling. Acta Hepatologica Japonica, 2015, 56, 575-583.	0.1	0
280	Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver International, 2015, 35, 636-641.	3.9	57
281	Predictive Scores in Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2015, 49, 438-447.	2.2	12
282	Chemokine (Câ€Xâ€C motif) ligand 13 promotes intrahepatic chemokine (Câ€Xâ€C motif) receptor 5+ lymphocyte homing and aberrant Bâ€cell immune responses in primary biliary cirrhosis. Hepatology, 2015, 61, 1998-2007.	7.3	45
283	Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. Alimentary Pharmacology and Therapeutics, 2015, 42, 221-230.	3.7	42
284	Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease. Medicine (United States), 2015, 94, e1243.	1.0	14
285	Autoimmune liver disease and concomitant extrahepatic autoimmune disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1175-1179.	1.6	60
286	A Concise Review of Autoimmune Liver Diseases. , 0, , .		3
287	Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World Journal of Hepatology, 2015, 7, 926.	2.0	84
288	Clinical Features and Response to UDCA Treatment of Primary Biliary Cirrhosis. The Ewha Medical Journal, 2015, 38, 106.	0.2	0
289	Serum Cell Death Biomarkers for Prediction of Liver Fibrosis and Poor Prognosis in Primary Biliary Cirrhosis. PLoS ONE, 2015, 10, e0131658.	2.5	24

#	Article	IF	Citations
290	Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. Arquivos De Gastroenterologia, 2015, 52, 15-46.	0.8	11
292	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. Mediators of Inflammation, 2015, 2015, 1-12.	3.0	22
293	SP140L, an Evolutionarily Recent Member of the SP100 Family, Is an Autoantigen in Primary Biliary Cirrhosis. Journal of Immunology Research, 2015, 2015, 1-17.	2.2	13
294	Serum IgG Subclasses in Autoimmune Diseases. Medicine (United States), 2015, 94, e387.	1.0	79
295	Liver and the Biliary Tract. , 2015, , 1695-1717.		0
296	Human autoimmune diseases: a comprehensive update. Journal of Internal Medicine, 2015, 278, 369-395.	6.0	681
297	RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial: FigureÂ1. BMJ Open, 2015, 5, e007985.	1.9	19
299	Rifampin (INN Rifampicin). Journal of Pain and Symptom Management, 2015, 50, 891-895.	1.2	7
300	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, e57-e59.	1.5	36
301	Reply. Gastroenterology, 2015, 149, 508-509.	1.3	0
302	Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid. Digestive Diseases, 2015, 33, 125-133.	1.9	9
303	Pathogenesis and Management of Pruritus in PBC and PSC. Digestive Diseases, 2015, 33, 164-175.	1.9	61
304	Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis. Digestive Diseases, 2015, 33, 118-124.	1.9	4
305	Worldwide Incidence of Autoimmune Liver Disease. Digestive Diseases, 2015, 33, 2-12.	1.9	88
306	Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opinion on Pharmacotherapy, 2015, 16, 633-643.	1.8	31
307	The Coexistence of SjÃ¶gren's Syndrome and Primary Biliary Cirrhosis: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2015, 48, 301-315.	6.5	35
308	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology, 2015, 148, 751-761.e8.	1.3	470
309	Novel therapeutic targets in primary biliary cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 147-158.	17.8	110

#	Article	IF	Citations
312	Multiple Genetic Variants Associated with Primary Biliary Cirrhosis in a Han Chinese Population. Clinical Reviews in Allergy and Immunology, 2015, 48, 316-321.	6.5	42
313	Increased Numbers of Circulating ICOS+ Follicular Helper T and CD38+ Plasma Cells in Patients with Newly Diagnosed Primary Biliary Cirrhosis. Digestive Diseases and Sciences, 2015, 60, 405-413.	2.3	19
314	Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. Journal of Gastroenterology, 2015, 50, 675-682.	5.1	37
315	Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. Digestive and Liver Disease, 2015, 47, 877-883.	0.9	10
316	Role of Lipoylation of the Immunodominant Epitope of Pyruvate Dehydrogenase Complex: Toward a Peptide-Based Diagnostic Assay for Primary Biliary Cirrhosis. Journal of Medicinal Chemistry, 2015, 58, 6619-6629.	6.4	7
317	Primary biliary cirrhosis: safety and benefits of established and emerging therapies. Expert Opinion on Drug Safety, 2015, 14, 1435-1444.	2.4	8
318	Overlap syndromes of autoimmune hepatitis: diagnosis and treatment. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2015, 80, 150-159.	0.2	5
319	Glycyrrhizin, silymarin, and ursodeoxycholic acid regulate a common hepatoprotective pathway in HepG2 cells. Phytomedicine, 2015, 22, 768-777.	5.3	40
320	Primary biliary cirrhosis: proposal for a new simple histological scoring system. Liver International, 2015, 35, 652-659.	3.9	22
321	Towards the serological diagnosis of primary biliary cirrhosis. Liver International, 2015, 35, 299-301.	3.9	1
322	Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2015, 110, 857-864.	0.4	115
323	Antiâ€kelchâ€like 12 and antiâ€hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver International, 2015, 35, 642-651.	3.9	66
324	New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. Journal of Hepatology, 2015, 62, S25-S37.	3.7	406
325	ACG Clinical Guideline: Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2015, 110, 646-659.	0.4	400
326	Transplantation for Primary Biliary Cirrhosis. , 2015, , 159-166.		0
327	A possible involvement of endoplasmic reticulum stress in biliary epithelial autophagy and senescence in primary biliary cirrhosis. Journal of Gastroenterology, 2015, 50, 984-995.	5.1	52
328	Associations Between Magnetic Resonance Imaging Findings and Scores of Liver Function and Histology in Patients with Primary Biliary Cirrhosis. Applied Magnetic Resonance, 2015, 46, 731-739.	1.2	2
329	Women and Primary Biliary Cirrhosis. Clinical Reviews in Allergy and Immunology, 2015, 48, 285-300.	6.5	35

#	Article	IF	Citations
330	Unmet Challenges in Immune-Mediated Hepatobiliary Diseases. Clinical Reviews in Allergy and Immunology, 2015, 48, 127-131.	6.5	26
331	Characterization and treatment of persistent hepatocellular secretory failure. Liver International, 2015, 35, 1478-1488.	3.9	24
332	Scandinavian epidemiological research in gastroenterology and hepatology. Scandinavian Journal of Gastroenterology, 2015, 50, 636-648.	1.5	4
333	New simple prognostic score for primary biliary cirrhosis: Albuminâ€bilirubin score. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1391-1396.	2.8	95
334	S100A12 expression in patients with primary biliary cirrhosis. Immunological Investigations, 2015, 44, 13-22.	2.0	5
335	Autoantibody status and histological variables influence biochemical response to treatment and longâ€term outcomes in <scp>J</scp>apanese patients with primary biliary cirrhosis. Hepatology Research, 2015, 45, 846-855.	3.4	34
336	The Cholangiopathies. Mayo Clinic Proceedings, 2015, 90, 791-800.	3.0	167
337	Synthesis of diastereomerically pure Lys(N^{Îµ}â€lipoyl) building blocks and their use in Fmoc/tBu solid phase synthesis of lipoylâ€containing peptides for diagnosis of primary biliary cirrhosis. Journal of Peptide Science, 2015, 21, 408-414.	1.4	10
338	Oxidative stress and antioxidant status in patients with autoimmune liver diseases. Redox Report, 2015, 20, 33-41.	4.5	34
339	Network Meta-Analysis of Randomized Controlled Trials. Medicine (United States), 2015, 94, e609.	1.0	17
340	Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis. Clinical Reviews in Allergy and Immunology, 2015, 48, 132-141.	6.5	50
341	Mycobacteria and autoimmunity. Lupus, 2015, 24, 374-381.	1.6	29
342	Changing Nomenclature for PBC: From â€˜Cirrhosisâ€™ to â€˜Cholangitisâ€™. American Journal of Gastroenterology, 2015, 110, 1536-1538.	0.4	30
343	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Digestive and Liver Disease, 2015, 47, 924-926.	0.9	15
344	Changing Nomenclature for PBC: From â€˜Cirrhosisâ€™ to â€˜Cholangitisâ€™. Gastroenterology, 2015, 149, 1627-1629.	1.3	96
345	Changing Nomenclature for PBC: From â€˜Cirrhosisâ€™ to â€˜Cholangitisâ€™. Clinical Gastroenterology and Hepatology, 2015, 13, 1867-1869.	4.4	16
346	In recurrent primary biliary cirrhosis after liver transplantation, biliary epithelial cells show increased expression of mitochondrial proteins. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 417-425.	2.8	12
347	A decline of LAMP-2 predicts ursodeoxycholic acid response in primary biliary cirrhosis. Scientific Reports, 2015, 5, 9772.	3.3	4

#	Article	IF	Citations
348	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	1.3	330
349	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Journal of Hepatology, 2015, 63, 1285-1287.	3.7	85
350	Complications of cholestasis. Medicine, 2015, 43, 666-668.	0.4	1
351	Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. Journal of Hepatology, 2015, 63, 1449-1458.	3.7	84
352	Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2015, 6, e109.	2.5	23
353	Changing nomenclature for PBC: from â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Gut, 2015, 64, 1671-1672.	12.1	28
354	DiagnÃ³stico y tratamiento de los sÃndromes de sobreposiciÃ³n de hepatitis autoinmune. Revista De GastroenterologÃa De MÃ©xico, 2015, 80, 150-159.	0.2	7
355	Primary biliary cirrhosis. Lancet, The, 2015, 386, 1565-1575.	13.7	502
356	Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. Liver International, 2015, 35, 263-274.	3.9	57
357	Diagnosis and Management of Overlap Syndromes. Clinics in Liver Disease, 2015, 19, 81-97.	2.1	30
358	New Therapies for Primary Biliary Cirrhosis. Clinical Reviews in Allergy and Immunology, 2015, 48, 263-272.	6.5	34
359	CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology, 2015, 61, 627-638.	7.3	104
360	Lysophosphatidic acid and signaling in sensory neurons. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 61-65.	2.4	19
361	Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. Clinica Chimica Acta, 2015, 438, 135-138.	1.1	31
362	Liver damage in primary biliary cirrhosis and accompanied by primary SjÃ¶grenâ€™s syndrome: a retrospective pilot study. Central-European Journal of Immunology, 2016, 2, 182-187.	1.2	8
363	Cirrhosis and autoimmune liver disease: Current understanding. World Journal of Hepatology, 2016, 8, 1157.	2.0	47
364	Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: A systematic review. Journal of Clinical and Translational Hepatology, 2016, 4, 192-205.	1.4	17
365	Recent advances in understanding and managing cholestasis. F1000Research, 2016, 5, 705.	1.6	46

#	Article	IF	Citations
366	A Patient With Primary Biliary Cirrhosis Accompanied by Wilsonâ€™s Disease. Hepatitis Monthly, 2016, 16, e29077.	0.2	1
367	Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut and Liver, 2016, 10, 177.	2.9	124
368	Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepatic Medicine: Evidence and Research, 2016, Volume 8, 89-95.	2.5	35
369	Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases. Diseases (Basel, Switzerland), 2016, 4, 38.	2.5	4
370	Interleukin-17A-Induced Epithelial-Mesenchymal Transition of Human Intrahepatic Biliary Epithelial Cells: Implications for Primary Biliary Cirrhosis. Tohoku Journal of Experimental Medicine, 2016, 240, 269-275.	1.2	24
371	Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update. Journal of Managed Care & Specialty Pharmacy, 2016, 22, S3-S15.	0.9	23
372	Vitamin D deficiency in patients with liver cirrhosis. Annals of Gastroenterology, 2016, 29, 297-306.	0.6	67
373	Bile acid derivatives for people with primary biliary cholangitis. The Cochrane Library, 0, , .	2.8	0
374	Recent advances in the diagnosis and treatment of primary biliary cholangitis. World Journal of Hepatology, 2016, 8, 1419.	2.0	24
375	The relationship between liver histology and noninvasive markers in primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2016, 28, 773-776.	1.6	25
376	Low incidence of primary biliary cirrhosis (<scp>PBC</scp>) in the firstâ€degree relatives of <scp>PBC</scp> probands after 8 years of followâ€up. Liver International, 2016, 36, 1378-1382.	3.9	22
377	The dynamic and clinical significance of autoantibodies and immunoglobulins in liver transplant recipients. Clinical Transplantation, 2016, 30, 241-246.	1.6	3
378	Primary biliary cholangitis associated with warm autoimmune hemolytic anemia. Journal of Digestive Diseases, 2016, 17, 128-131.	1.5	5
379	The UKâ€PBC risk scores: Derivation and validation of a scoring system for longâ€term prediction of endâ€stage liver disease in primary biliary cholangitis. Hepatology, 2016, 63, 930-950.	7.3	269
380	It is time to change primary biliary cirrhosis (PBC): New nomenclature from â€œcirrhosisâ€œ to â€œcholangitisâ€, and upcoming treatment based on unveiling pathology. Hepatology Research, 2016, 46, 407-415.	3.4	8
381	Highâ€throughput Tâ€cell receptor sequencing across chronic liver diseases reveals distinct diseaseâ€associated repertoires. Hepatology, 2016, 63, 1608-1619.	7.3	104
382	Impact of serumWisteria floribundaagglutinin positive Mac-2-binding protein and serum interferon-Î³-inducible protein-10 in primary biliary cirrhosis. Hepatology Research, 2016, 46, 575-583.	3.4	40
383	The expression of miRâ€125bâ€5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen. Journal of Viral Hepatitis, 2016, 23, 330-339.	2.0	35

#	Article	IF	Citations
384	Bile Acids and the Potential Role in Primary Biliary Cirrhosis. Digestion, 2016, 94, 145-153.	2.3	28
385	Cholestatic Liver Injury: Care of Patients With Primary Biliary Cholangitis or Primary Sclerosing Cholangitis. AACN Advanced Critical Care, 2016, 27, 441-452.	1.1	5
386	Tauroursodeoxycholic acid reduces ER stress by regulating of Akt-dependent cellular prion protein. Scientific Reports, 2016, 6, 39838.	3.3	97
387	A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (United States), 2016, 95, e5391.	1.0	27
389	Targets and investigative treatments for primary biliary cholangitis. Expert Opinion on Orphan Drugs, 2016, 4, 1011-1020.	0.8	0
390	Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). Autoimmunity Reviews, 2016, 15, 795-800.	5.8	31
391	The protective effect of juglanin on fructose-induced hepatitis by inhibiting inflammation and apoptosis through TLR4 and JAK2/STAT3 signaling pathways in fructose-fed rats. Biomedicine and Pharmacotherapy, 2016, 81, 318-328.	5.6	49
393	A case of an elderly patient with primary biliary cirrhosis. European Geriatric Medicine, 2016, 7, 366-368.	2.8	0
394	Novel bile acid therapeutics for the treatment of chronic liver diseases. Therapeutic Advances in Gastroenterology, 2016, 9, 376-391.	3.2	38
395	73-Year-Old Woman With Pruritus, Jaundice, and Altered Mental Status. Mayo Clinic Proceedings, 2016, 91, 1287-1291.	3.0	0
396	Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis. Medicine (United States), 2016, 95, e3114.	1.0	38
397	Novel Aspects in the Management of Cholestatic Liver Diseases. Digestive Diseases, 2016, 34, 340-346.	1.9	15
398	The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 553-561.	1.5	27
399	Itch Management: Physical Approaches (UV Phototherapy, Acupuncture). Current Problems in Dermatology, 2016, 50, 54-63.	0.7	8
400	MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis. Laboratory Investigation, 2016, 96, 1165-1177.	3.7	28
401	Management of Esophageal Variceal Bleeding. , 2016, , 27-39.		0
402	The interâ€relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 1039-1050.	3.7	54
403	Molecular diagnostic testing for primary biliary cholangitis. Expert Review of Molecular Diagnostics, 2016, 16, 1001-1010.	3.1	30

#	Article	IF	Citations
404	The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Alimentary Pharmacology and Therapeutics, 2016, 43, 294-302.	3.7	56
405	Obeticholic acid for the treatment of primary biliary cholangitis. Expert Opinion on Pharmacotherapy, 2016, 17, 1809-1815.	1.8	39
406	Combined ursodeoxycholic acid (<scp>UDCA</scp>) and fenofibrate in primary biliary cholangitis patients with incomplete <scp>UDCA</scp> response may improve outcomes. Alimentary Pharmacology and Therapeutics, 2016, 43, 283-293.	3.7	109
407	Editorial: improved understanding of the epidemiology of primary biliary cirrhosis in South Korea. Alimentary Pharmacology and Therapeutics, 2016, 43, 650-651.	3.7	0
408	Elevation of VÎ´1 T cells in peripheral blood and livers of patients with primary biliary cholangitis. Clinical and Experimental Immunology, 2016, 186, 347-355.	2.6	5
409	Changes of four common non-infectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013. Alcohol, 2016, 54, 61-65.	1.7	5
410	Primary Biliary Cholangitis â€" A New Name and a New Treatment. New England Journal of Medicine, 2016, 375, 685-687.	27.0	10
411	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	27.0	817
412	Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1091-1099.	3.0	12
413	Autoimmune liver diseases in the Asiaâ€"Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. Hepatology International, 2016, 10, 909-915.	4.2	41
414	Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. Digestive Diseases and Sciences, 2016, 61, 3037-3044.	2.3	65
415	Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan. Scientific Reports, 2016, 6, 29770.	3.3	27
416	Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics. Journal of Clinical and Experimental Hepatology, 2016, 6, 311-318.	0.9	26
417	Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis. SpringerPlus, 2016, 5, 777.	1.2	29
418	The assessment of subjective symptoms and patient-reported outcomes in patients with primary biliary cholangitis using PBC-40. Acta Hepatologica Japonica, 2016, 57, 457-467.	0.1	5
419	BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMC Gastroenterology, 2016, 16, 71.	2.0	31
420	Acute-on-chronic and Decompensated Chronic Liver Failure. Critical Care Clinics, 2016, 32, 301-309.	2.6	15
422	Toward precision medicine in primary biliary cholangitis. Digestive and Liver Disease, 2016, 48, 843-850.	0.9	12

#	Article	IF	Citations
424	Prognostic implications of extra-hepatic clinical manifestations, autoimmunity and microscopic nail capillaroscopy in patients with primary biliary cirrhosis. Medicina ClÃnica (English Edition), 2016, 146, 8-15.	0.2	0
425	Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report. Gastroenterology Report, 2016, 5, gov064.	1.3	2
426	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	12.1	139
427	Autoimmune Hepatitis Type 2 Associated With Positive Antimitochondrial Antibodies. Clinical Pediatrics, 2016, 55, 479-482.	0.8	5
428	Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scandinavian Journal of Gastroenterology, 2016, 51, 745-752.	1.5	36
429	Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2016, 61, 1692-1699.	2.3	49
430	Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Review of Clinical Pharmacology, 2016, 9, 13-26.	3.1	51
431	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology, 2016, 63, 644-659.	7.3	57
432	Therapeutic advances for primary biliary cholangitis: the old and the new. European Journal of Gastroenterology and Hepatology, 2016, 28, 615-621.	1.6	7
433	ACG Clinical Guideline: Liver Disease and Pregnancy. American Journal of Gastroenterology, 2016, 111, 176-194.	0.4	199
434	Emerging drugs for the treatment of Primary Biliary Cholangitis. Expert Opinion on Emerging Drugs, 2016, 21, 39-56.	2.4	16
435	Novel Therapies on Primary Biliary Cirrhosis. Clinics in Liver Disease, 2016, 20, 113-130.	2.1	8
436	Proposed therapies in primary biliary cholangitis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 371-382.	3.0	10
437	Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinics in Liver Disease, 2016, 20, 131-142.	2.1	16
438	The management of autoimmunity in patients with cholestatic liver diseases. Expert Review of Gastroenterology and Hepatology, 2016, 10, 73-91.	3.0	12
439	The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis. Clinical Reviews in Allergy and Immunology, 2016, 50, 114-123.	6.5	53
440	Liver Transplantation for Cholestatic Liver Diseases in Adults. Clinics in Liver Disease, 2016, 20, 191-203.	2.1	39
441	A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. Frontline Gastroenterology, 2016, 7, 158-166.	1.8	26

#	Article	IF	Citations
442	Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity. Clinical Reviews in Allergy and Immunology, 2016, 50, 390-403.	6.5	33
444	The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. Cellular and Molecular Immunology, 2017, 14, 276-284.	10.5	51
445	A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. American Journal of Therapeutics, 2017, 24, e167-e176.	0.9	46
446	Update on pharmacotherapies for cholestatic liver disease. Hepatology Communications, 2017, 1, 7-17.	4.3	16
447	Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Modern Pathology, 2017, 30, 773-783.	5.5	79
448	Diagnostic considerations for cholestatic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1303-1309.	2.8	37
449	Genome-wide association studies identifyPRKCBas a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. Human Molecular Genetics, 2017, 26, ddw406.	2.9	46
450	Comparison between realâ€time tissue elastography and vibrationâ€controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis. Hepatology Research, 2017, 47, 1252-1259.	3.4	18
451	The risk predictive values of <scp>UK</scp>â€<scp>PBC</scp> and <scp>GLOBE</scp> scoring system in Chinese patients with primary biliary cholangitis: the additional effect of antiâ€gp210. Alimentary Pharmacology and Therapeutics, 2017, 45, 733-743.	3.7	61
452	Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 299-309.	2.3	14
453	Bile acids and cardiovascular function in cirrhosis. Liver International, 2017, 37, 1420-1430.	3.9	44
454	Liver immunology. , 2017, , 173-187.e2.		0
455	Primary biliary cholangitis: new treatments for an old disease. Frontline Gastroenterology, 2017, 8, 29-36.	1.8	8
456	Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8+ T cell activation. Journal of Autoimmunity, 2017, 78, 19-28.	6.5	28
457	Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet, The, 2017, 389, 1114-1123.	13.7	157
458	Bile Acids and Deregulated Cholangiocyte Autophagy in Primary Biliary Cholangitis. Digestive Diseases, 2017, 35, 210-216.	1.9	26
459	Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. American Journal of Medicine, 2017, 130, 744.e1-744.e7.	1.5	28
460	Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. Digestive Diseases and Sciences, 2017, 62, 1363-1372.	2.3	4

#	Article	IF	Citations
461	miR-425 regulates inflammatory cytokine production in CD4+ T cells via N-Ras upregulation in primary biliary cholangitis. Journal of Hepatology, 2017, 66, 1223-1230.	3.7	37
462	Geoepidemiology and changing mortality in primary biliary cholangitis. Journal of Gastroenterology, 2017, 52, 655-662.	5.1	16
463	A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nature Communications, 2017, 8, 14828.	12.8	102
464	Apamin suppresses biliary fibrosis and activation of hepatic stellate cells. International Journal of Molecular Medicine, 2017, 39, 1188-1194.	4.0	17
465	Obeticholic Acid. Journal of Pharmacy Technology, 2017, 33, 66-71.	1.0	6
466	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology, 2017, 67, 145-172.	3.7	889
467	Diagnostic autoantibodies for autoimmune liver diseases. Clinical and Translational Immunology, 2017, 6, e139.	3.8	22
468	Primary Biliary Cholangitis: advances in management and treatment of the disease. Digestive and Liver Disease, 2017, 49, 841-846.	0.9	23
470	The emerging role of mast cells in liver disease. American Journal of Physiology - Renal Physiology, 2017, 313, G89-G101.	3.4	34
471	What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?. Digestive Diseases, 2017, 35, 359-366.	1.9	8
472	American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. Gastroenterology, 2017, 152, 1536-1543.	1.3	121
473	Pathological Features of Biliary Disease in Children and Adults. , 2017, , 43-61.		0
474	Primary Biliary Cholangitis: Its Science and Practice. , 2017, , 129-182.		0
475	Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. Gastroenterology Clinics of North America, 2017, 46, 345-364.	2.2	22
476	Treatment of primary biliary cholangitis ursodeoxycholic acid nonâ€responders: A systematic review. Liver International, 2017, 37, 1877-1886.	3.9	27
477	Coexistent Primary Biliary Cholangitis with CREST Syndrome (Reynolds Syndrome). American Journal of Medicine, 2017, 130, e501-e502.	1.5	5
478	Endoscopy in Pregnant Women With Liver Cirrhosis. Gastroenterology, 2017, 153, 329-330.	1.3	1
479	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2017, 37, 159-174.	3.6	26

#	Article	IF	Citations
480	Finding the cure for primary biliary cholangitis â€“ Still waiting. Liver International, 2017, 37, 500-502.	3.9	21
481	The Clinical Burden of Biliary Disease: A Global Perspective. , 2017, , 1-15.		1
482	Pharmacological interventions for primary biliary cholangitis. The Cochrane Library, 2017, 2017, CD011648.	2.8	21
483	Old and new treatments for primary biliary cholangitis. Liver International, 2017, 37, 490-499.	3.9	37
484	Human Î²-Defensin 2 in Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2017, 8, e80.	2.5	3
485	Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis. Toxicology, 2017, 377, 73-80.	4.2	8
486	ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology, 2017, 112, 18-35.	0.4	672
487	Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Clinical Reviews in Allergy and Immunology, 2017, 53, 394-412.	6.5	27
488	Incidence of Primary Biliary Cholangitis in a Rural Midwestern Population. Clinical Medicine and Research, 2017, 15, 13-18.	0.8	12
489	Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona. BMJ Open Gastroenterology, 2017, 4, e000158.	2.7	3
490	Novel strategies and therapeutic options for the management of primary biliary cholangitis. Therapeutic Advances in Gastroenterology, 2017, 10, 791-803.	3.2	12
491	Investigational drugs in phase II clinical trials for primary biliary cholangitis. Expert Opinion on Investigational Drugs, 2017, 26, 1115-1121.	4.1	6
492	A brief review on prognostic models of primary biliary cholangitis. Hepatology International, 2017, 11, 412-418.	4.2	15
493	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clinical and Translational Gastroenterology, 2017, 8, e116.	2.5	48
494	Association of autoimmune hepatitis with Src homology 2 adaptor protein 3 gene polymorphisms in Japanese patients. Journal of Human Genetics, 2017, 62, 963-967.	2.3	20
495	The Challenges of Nutritional Assessment in Cirrhosis. Current Nutrition Reports, 2017, 6, 274-280.	4.3	13
496	Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwichâ€cultured human hepatocytes. Pharmacology Research and Perspectives, 2017, 5, e00329.	2.4	36
497	Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmunity Reviews, 2017, 16, 885-896.	5.8	158

#	Article	IF	Citations
498	Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba. Current Therapeutic Research, 2017, 85, 8-14.	1.2	2
499	An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis. Clinics in Liver Disease, 2017, 21, 709-723.	2.1	10
500	Toward solving the etiological mystery of primary biliary cholangitis. Hepatology Communications, 2017, 1, 275-287.	4.3	28
501	Circulating follicular helper T cells presented distinctively different responses toward bacterial antigens in primary biliary cholangitis. International Immunopharmacology, 2017, 51, 76-81.	3.8	8
503	Less Limb Muscle Involvement in Myositis Patients with Anti-Mitochondrial Antibodies. European Neurology, 2017, 78, 290-295.	1.4	22
504	Primary biliary cholangitis: symptoms, diagnosis and treatment. Gastrointestinal Nursing, 2017, 15, S12-S17.	0.1	1
505	Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. Scientific Reports, 2017, 7, 15307.	3.3	72
506	A Mouse Model of Autoimmune Cholangitis via Syngeneic Bile Duct Protein Immunization. Scientific Reports, 2017, 7, 15246.	3.3	3
507	Gallbladder and bile duct disease in Cystic Fibrosis. Journal of Cystic Fibrosis, 2017, 16, S62-S69.	0.7	42
508	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. Clinical and Translational Gastroenterology, 2017, 8, e100.	2.5	23
509	Why Doesnâ€™t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?. Current Hepatology Reports, 2017, 16, 119-123.	0.9	12
510	Obeticholic acid in primary biliary cholangitis. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 3-5.	1.5	7
511	Lipoprotein-X in cholestatic patients causes xanthomas and promotes foam cell formation in human macrophages. Journal of Clinical Lipidology, 2017, 11, 110-118.	1.5	20
512	Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis. Clinica Chimica Acta, 2017, 464, 113-117.	1.1	22
513	Prevalence of Systemic Sclerosis in Primary Biliary Cholangitis Using the New ACR/EULAR Classification Criteria. Journal of Rheumatology, 2017, 44, 33-39.	2.0	23
514	Distinctive HLAâ€‖ association with primary biliary cholangitis on the Island of Sardinia. United European Gastroenterology Journal, 2017, 5, 527-531.	3.8	11
515	Evidence for the association between IgGâ€antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 659-666.	2.8	15
516	Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?. Immunologic Research, 2017, 65, 299-306.	2.9	4

#	Article	IF	Citations
517	Ganglionic acetylcholine receptor autoantibodies in patients with autoimmune diseases including primary biliary cirrhosis. Modern Rheumatology, 2017, 27, 664-668.	1.8	18
518	Positive antimitochondrial antibody but normal serum alkaline phosphatase levels: Could it be primary biliary cholangitis?. Hepatology Research, 2017, 47, 742-746.	3.4	10
519	Extensive testing or focused testing of patients with elevated liver enzymes. Journal of Hepatology, 2017, 66, 313-319.	3.7	28
520	Largeâ€scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology, 2017, 65, 152-163.	7.3	93
521	Association between serum soluble <scp>CD</scp>14 and <scp>IL</scp>â€8 levels and clinical outcome in primary biliary cholangitis. Liver International, 2017, 37, 897-905.	3.9	22
523	Imaging of autoimmune biliary disease. Abdominal Radiology, 2017, 42, 3-18.	2.1	10
524	Stress-induced cellular responses and cell death mechanisms during inflammatory cholangiopathies. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 129-138.	1.5	10
526	Chromosome 17q21 Genes ORMDL3 and GSDMB in Asthma and Immune Diseases. Advances in Immunology, 2017, 135, 1-52.	2.2	91
527	Pathological patterns of biliary disease. Clinical Liver Disease, 2017, 10, 107-110.	2.1	12
528	Anti-mitochondrial autoantibodiesâ€"milestone or byway to primary biliary cholangitis?. Annals of Translational Medicine, 2017, 5, 50-50.	1.7	4
529	Serological tests for primary biliary cholangitis. The Cochrane Library, 2017, , .	2.8	0
530	Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability. Annals of Hepatology, 2017, 16, 430-435.	1.5	9
531	Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study. BMJ Open Gastroenterology, 2017, 4, e000177.	2.7	1
532	Ursodeoxycholic Acid for the Treatment of Liver Diseases. , 2017, , 767-779.		2
534	Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans. Archives of Medical Science, 2018, 14, 930-940.	0.9	3
535	Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget, 2017, 8, 16498-16506.	1.8	35
536	Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis. Journal of Immunology Research, 2017, 2017, 1-6.	2.2	17
537	Risk of liver disease in methotrexate treated patients. World Journal of Hepatology, 2017, 9, 1092.	2.0	111

#	Article	IF	Citations
538	Reversal of liver cirrhosis: current evidence and expectations. Korean Journal of Internal Medicine, 2017, 32, 213-228.	1.7	100
539	Elevated Liver Enzymes in Asymptomatic Patients â€“ What Should I Do?. Journal of Clinical and Translational Hepatology, 2017, 5, 1-10.	1.4	67
540	Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS ONE, 2017, 12, e0178580.	2.5	36
541	MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients. PLoS ONE, 2017, 12, e0184292.	2.5	16
542	A case of asymptomatic non-cirrhotic primary biliary cholangitis showing splenorenal shunt with neither anti-mitochondrial antibody nor M2 antibody. Acta Hepatologica Japonica, 2017, 58, 38-45.	0.1	1
543	Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis. Scientific Reports, 2017, 7, 796.	3.3	12
544	[RETRACTED ARTICLE] Characteristics of liver fibrosis with different etiologies using a fully quantitative fibrosis assessment tool. Brazilian Journal of Medical and Biological Research, 2017, 50, e5234.	1.5	1
545	Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis. International Journal of Molecular Sciences, 2017, 18, 214.	4.1	24
546	The role of ursodeoxycholic acid on cholestatic hepatic fibrosis in infant rats. Molecular Medicine Reports, 2017, 17, 3837-3844.	2.4	4
547	Extrahepatic Manifestations of Primary Biliary Cholangitis. Gut and Liver, 2017, 11, 771-780.	2.9	61
548	Implication of increased serum stromal cell-derived factor-1 for primary biliary cholangitis. International Immunopharmacology, 2018, 56, 285-290.	3.8	5
549	Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a crossâ€disease cohort study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1213-1219.	3.7	23
550	Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and SjÃ¶gren syndrome. Medicine (United States), 2018, 97, e0004.	1.0	8
551	Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort. United European Gastroenterology Journal, 2018, 6, 247-254.	3.8	10
552	Metabolomics Profiles of Hepatocellular Carcinoma in a Korean Prospective Cohort: The Korean Cancer Prevention Study-II. Cancer Prevention Research, 2018, 11, 303-312.	1.5	45
554	Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures. Current Hepatology Reports, 2018, 17, 143-151.	0.9	1
555	Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. Journal of Gastroenterology, 2018, 53, 1151-1158.	5.1	29
556	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis Bâ€endemic area. Alimentary Pharmacology and Therapeutics, 2018, 47, 1490-1501.	3.7	22

#	Article	IF	Citations
557	Clinical connection between rheumatoid arthritis and liver damage. Rheumatology International, 2018, 38, 715-724.	3.0	40
558	Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. Medical Molecular Morphology, 2018, 51, 176-185.	1.0	5
559	Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis. Hepatology Research, 2018, 48, 727-734.	3.4	4
560	Persistent reduction of mucosalâ€associated invariant T cells in primary biliary cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1286-1294.	2.8	22
561	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 282-294.	6.5	36
562	Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Clinical Reviews in Allergy and Immunology, 2018, 54, 295-306.	6.5	12
563	Definitions, Epidemiology and Prognostication of Liver Disease. , 2018, , 75-82.		2
564	Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation. Digestive Diseases and Sciences, 2018, 63, 529-532.	2.3	5
565	Itching to Know: Role of Fibrates in PBC. American Journal of Gastroenterology, 2018, 113, 56-57.	0.4	3
566	Evaluation of abnormal liver tests in the adult asymptomatic patient. Current Opinion in Gastroenterology, 2018, 34, 272-279.	2.3	9
567	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut, 2018, 67, 1568-1594.	12.1	217
568	Colangitis biliar primaria. Medicina ClÃnica, 2018, 151, 242-249.	0.6	14
569	An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis. Laboratory Investigation, 2018, 98, 745-754.	3.7	29
570	Monoclonal gammopathy in rheumatic diseases. Clinical Rheumatology, 2018, 37, 1751-1762.	2.2	22
571	Red blood cell distribution width to platelet ratio levels in assessment of histologic severity in patients with primary biliary cholangitis. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 258-263.	1.2	9
572	Autoimmune manifestations of infections. Current Opinion in Rheumatology, 2018, 30, 373-379.	4.3	24
573	Platelet count to spleen thickness ratio is related to histologic severity of primary biliary cholangitis. Medicine (United States), 2018, 97, e9843.	1.0	5
574	Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut, 2018, 67, 534-541.	12.1	330

#	Article	IF	Citations
575	Possible involvement of chemokine Câ€C receptor 7^{â^'}programmed cell deathâ€1⁺ follicular helper Tâ€cell subset in the pathogenesis of autoimmune hepatitis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 298-306.	2.8	18
576	Primary biliary cholangitis: Old and novel therapy. European Journal of Internal Medicine, 2018, 47, 1-5.	2.2	54
577	Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. Journal of Clinical and Experimental Hepatology, 2018, 8, 156-161.	0.9	23
578	Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. Clinical Gastroenterology and Hepatology, 2018, 16, 1333-1341.e6.	4.4	42
579	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902.	7.3	204
580	Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. Seminars in Arthritis and Rheumatism, 2018, 47, 849-857.	3.4	16
581	Prevalence of pruritus in patients with chronic liver disease: A multicenter study. Hepatology Research, 2018, 48, E252-E262.	3.4	37
582	Clonal characteristics of paired infiltrating and circulating B lymphocyte repertoire in patients with primary biliary cholangitis. Liver International, 2018, 38, 542-552.	3.9	8
583	Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. Liver International, 2018, 38, 399-411.	3.9	30
584	Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. Clinical Journal of Gastroenterology, 2018, 11, 11-18.	0.8	36
585	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.4	64
586	Scratching the surface of cholestatic itch treatments. Hepatology, 2018, 67, 2045-2048.	7.3	4
587	Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. Liver International, 2018, 38, 1110-1116.	3.9	8
588	Gastrointestinal and Hepatic Disease in Sjogren Syndrome. Rheumatic Disease Clinics of North America, 2018, 44, 143-151.	1.9	29
589	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	7.3	55
591	Using the Icelandic genealogical database to define the familial risk of primary biliary cholangitis. Hepatology, 2018, 68, 166-171.	7.3	18
592	MicroRevolution in understanding primary biliary cholangitis pathophysiology. Hepatology, 2018, 67, 1213-1215.	7.3	1
593	An Argument for Vitamin D, A, and Zinc Monitoring in Cirrhosis. Annals of Hepatology, 2018, 17, 920-932.	1.5	21

#	Article	IF	Citations
594	Increased red cell width distribution to lymphocyte ratio is a predictor of histologic severity in primary biliary cholangitis. Medicine (United States), 2018, 97, e13431.	1.0	13
595	Primary biliary cholangitis: an update on treatment. Gastrointestinal Nursing, 2018, 16, S10-S14.	0.1	0
596	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Revista Espanola De Enfermedades Digestivas, 2018, 110, 641-649.	0.3	3
597	Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Research, 2018, 11, 83-94.	1.3	50
598	Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study. CMAJ Open, 2018, 6, E664-E670.	2.4	12
599	Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma. Journal of Liver, 2018, 07, .	0.3	6
600	Managing PBC: Expanding the Provider Comfort Zone. Digestive Diseases and Sciences, 2018, 63, 2487-2488.	2.3	0
601	Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 231, 180-187.	1.1	135
602	Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?. Journal of Hepatology, 2018, 69, 1371-1383.	3.7	35
603	NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Hepatology Communications, 2018, 2, 1037-1050.	4.3	96
604	Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS ONE, 2018, 13, e0203084.	2.5	43
605	Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis. Scientific Reports, 2018, 8, 12542.	3.3	17
606	Cholestatic liver diseases: new targets, new therapies. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481878740.	3.2	61
607	Regulation of bile secretion by calcium signaling in health and disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 1761-1770.	4.1	22
608	Understanding and Treating Pruritus in Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 517-532.	2.1	21
609	Current Treatment Options for Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 481-500.	2.1	9
610	Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. Scientific Reports, 2018, 8, 8159.	3.3	32
611	Pharmacotherapy for Alcohol Use Disorder in the Context of Liver Disease. Current Addiction Reports, 2018, 5, 287-296.	3.4	7

#	Article	IF	Citations
612	Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS ONE, 2018, 13, e0198757.	2.5	69
613	Evolution of our understanding of PBC. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 3-9.	2.4	29
614	The Genetics and Epigenetics of Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 443-455.	2.1	27
615	Natural History of Primary Biliary Cholangitis in the Ursodeoxycholic Acid Era. Clinics in Liver Disease, 2018, 22, 563-578.	2.1	32
616	Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 603-611.	2.1	17
617	Distribution of Connective Tissue in the Male and Female Porcine Liver: Histological Mapping and Recommendations for Sampling. Journal of Comparative Pathology, 2018, 162, 1-13.	0.4	13
618	Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis. Clinical and Translational Gastroenterology, 2018, 9, e169.	2.5	13
619	Association between STAT4 polymorphisms and risk of primary biliary cholangitis: a meta-analysis. Genes and Genomics, 2018, 40, 1101-1109.	1.4	1
620	Deviations in Peripheral Blood Cell Populations are Associated with the Stage of Primary Biliary Cholangitis and Presence of Itching. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 443-452.	2.3	13
621	Liver Illness and Psoriatic Patients. BioMed Research International, 2018, 2018, 1-12.	1.9	52
622	Symptoms of PBC â€“ Pathophysiology and management. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 41-47.	2.4	22
623	Biomarkers for primary biliary cholangitis: current perspectives. Hepatic Medicine: Evidence and Research, 2018, Volume 10, 43-53.	2.5	16
624	A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. BMC Gastroenterology, 2018, 18, 97.	2.0	5
625	Bile Duct Diseases. , 2018, , 515-593.		12
626	Antimitochondrial Antibodyâ€“Negative Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 589-601.	2.1	11
627	Current Status of Liver Transplantation for Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 613-624.	2.1	20
628	Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: Analysis of a cohort of 214 patients. Autoimmunity Reviews, 2018, 17, 866-872.	5.8	22
629	Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness. Digestive Diseases and Sciences, 2018, 63, 2547-2554.	2.3	6

#	Article	IF	Citations
630	External validation of the United Kingdomâ€primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Hepatology Communications, 2018, 2, 676-682.	4.3	6
631	Primary biliary cholangitis. Medicina ClÃnica (English Edition), 2018, 151, 242-249.	0.2	4
632	Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDPâ€305, a novel farnesoid X receptor agonist. Hepatology Communications, 2018, 2, 821-835.	4.3	46
633	Work in Progress. Clinics in Liver Disease, 2018, 22, 501-515.	2.1	1
634	Chronic Complications of Cholestasis. Clinics in Liver Disease, 2018, 22, 533-544.	2.1	21
635	Primary Biliary Cholangitis. , 2018, , 409-421.		0
636	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. New England Journal of Medicine, 2018, 378, 2171-2181.	27.0	383
637	Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment. European Journal of Gastroenterology and Hepatology, 2018, 30, 1352-1360.	1.6	6
639	A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity. Internal Medicine, 2018, 57, 3093-3097.	0.7	0
640	Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). PLoS ONE, 2018, 13, e0193960.	2.5	22
641	Patterns of disease progression and incidence of complications in primary biliary cholangitis (PBC). Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 71-83.	2.4	10
642	Improving prognosis in primary biliary cholangitis â€“ Therapeutic options and strategy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 85-94.	2.4	10
643	Risk stratification and prognostic modelling in primary biliary cholangitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 95-106.	2.4	10
644	Clinical application of the GLOBE and United Kingdomâ€primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. Hepatology Communications, 2018, 2, 683-692.	4.3	19
645	Asociaciones autoinmunes en una cohorte mexicana con colangitis biliar primaria. Revista De GastroenterologÃa De MÃ©xico, 2019, 84, 130-135.	0.2	6
646	Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial. Hepatology, 2019, 70, 1646-1657.	7.3	48
647	Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. Hepatology, 2019, 69, 237-244.	7.3	18
648	High occurrence of small intestinal bacterial overgrowth in primary biliary cholangitis. Neurogastroenterology and Motility, 2019, 31, e13691.	3.0	14

#	Article	IF	Citations
649	A National Hospitalâ€Based Study of Hospitalized Patients With Primary Biliary Cholangitis. Hepatology Communications, 2019, 3, 1250-1257.	4.3	11
650	Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population. Journal of Clinical Laboratory Analysis, 2019, 33, e22965.	2.1	27
651	Endocrine Diseases and the Liver. Clinics in Liver Disease, 2019, 23, 233-246.	2.1	20
652	Concomitant SjÃ¶grenâ€™s Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology, 2019, 2019, 1-6.	1.9	9
653	Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. International Journal of Molecular Sciences, 2019, 20, 5055.	4.1	140
654	Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. Scandinavian Journal of Gastroenterology, 2019, 54, 1391-1396.	1.5	8
655	Cholestatic pruritus: Emerging mechanisms and therapeutics. Journal of the American Academy of Dermatology, 2019, 81, 1371-1378.	1.2	23
656	Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key?. Journal of Clinical Pathology, 2019, 72, 669-676.	2.0	9
657	Epidemiology and clinical course of primary biliary cholangitis in the Asiaâ€“Pacific region: a systematic review and meta-analysis. Hepatology International, 2019, 13, 788-799.	4.2	44
658	Epigenetic Modifications in Generalized Autoimmune Epithelitis: SjÃ¶grenâ€™s Syndrome and Primary Biliary Cholangitis. Epigenomes, 2019, 3, 15.	1.8	7
659	CD4⁺ T cells from patients with primary biliary cholangitis show T cell activation and differentially expressed Tâ€cell receptor repertoires. Hepatology Research, 2019, 49, 653-662.	3.4	4
660	Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study. Scandinavian Journal of Gastroenterology, 2019, 54, 609-616.	1.5	20
661	Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor Î±/Î´ Agonist for the Treatment of Primary Biliary Cirrhosis. ACS Medicinal Chemistry Letters, 2019, 10, 1068-1073.	2.8	5
662	Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Research, 2019, 3, 118-127.	1.4	5
663	Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. Canadian Liver Journal, 2019, 2, 31-44.	0.9	11
664	Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing Database. Transplantation, 2019, 103, 1191-1198.	1.0	3
665	Interleukinâ€33/ST2â€Mediated Inflammation Plays a Critical Role in the Pathogenesis and Severity of Type I Autoimmune Hepatitis. Hepatology Communications, 2019, 3, 670-684.	4.3	11
666	An ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of obeticholic acid in rat plasma and its application in preclinical pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1121, 82-88.	2.3	4

#	Article	IF	Citations
667	CTHRC1 expression in primary biliary cholangitis. Journal of Digestive Diseases, 2019, 20, 371-376.	1.5	7
668	Alteration of liverâ€infiltrated and peripheral blood doubleâ€negative Tâ€cells in primary biliary cholangitis. Liver International, 2019, 39, 1755-1767.	3.9	9
669	Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA. Frontiers in Immunology, 2019, 10, 1026.	4.8	31
670	Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. Clinical Gastroenterology and Hepatology, 2019, 17, 1379-1387.e3.	4.4	43
671	Proteomics in Primary Biliary Cholangitis. Methods in Molecular Biology, 2019, 1981, 163-173.	0.9	1
672	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. The Lancet Gastroenterology and Hepatology, 2019, 4, 445-453.	8.1	116
673	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	4.4	54
674	Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel. BMJ Open Gastroenterology, 2019, 6, e000256.	2.7	11
675	Genomeâ€wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis. Hepatology, 2019, 70, 294-307.	7.3	30
676	Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations. Scientific Reports, 2019, 9, 4530.	3.3	43
677	Analysis of predictive response scores to treatment with ursodeoxycholic acid in patients with primary biliary cholangitis. Medicina ClÃnica (English Edition), 2019, 152, 377-383.	0.2	0
678	Current and promising therapy for primary biliary cholangitis. Expert Opinion on Pharmacotherapy, 2019, 20, 1161-1167.	1.8	10
679	Bezafibrate Improves GLOBE and UKâ€PBC Scores and Longâ€Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology, 2019, 70, 2035-2046.	7.3	83
680	65-Year-Old Woman With Abdominal Pain and Jaundice. Mayo Clinic Proceedings, 2019, 94, e51-e55.	3.0	0
681	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. Hepatology Communications, 2019, 3, 365-381.	4.3	58
682	Liver assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging in primary biliary cholangitis patients. Japanese Journal of Radiology, 2019, 37, 412-419.	2.4	5
683	Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. Autoimmunity Highlights, 2019, 10, 10.	3.9	6
684	Genetic association of E26 transformation specific sequence 1 polymorphisms with the susceptibility of primary biliary cholangitis in China. Scientific Reports, 2019, 9, 19680.	3.3	2

#	Article	IF	Citations
685	Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 1593-1605.	0.4	28
686	Primary biliary cholangitis: an update on treatment. Gastrointestinal Nursing, 2019, 17, S14-S16.	0.1	0
687	Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. International Journal of Cancer, 2019, 144, 707-717.	5.1	20
688	Association of CCL11, CCL24 and CCL26 with primary biliary cholangitis. International Immunopharmacology, 2019, 67, 372-377.	3.8	6
689	Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Alimentary Pharmacology and Therapeutics, 2019, 49, 285-295.	3.7	37
690	Cholangiocyte death in ductopenic cholestatic cholangiopathies: Mechanistic basis and emerging therapeutic strategies. Life Sciences, 2019, 218, 324-339.	4.3	14
691	Idiopathic inflammatory myopathies with anti-mitochondrial antibodies: Clinical features and treatment outcomes in a Chinese cohort. Neuromuscular Disorders, 2019, 29, 5-13.	0.6	23
692	Diagnosis and Management of Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 48-63.	0.4	100
693	Changes in serum levels of leucineâ€rich Î±2â€glycoprotein predict prognosis in primary biliary cholangitis. Hepatology Research, 2019, 49, 385-393.	3.4	9
694	Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Frontline Gastroenterology, 2019, 10, 401-408.	1.8	14
695	Autoimmune associations in a Mexican cohort with primary biliary cholangitis. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2019, 84, 130-135.	0.2	2
696	AnÃ¡lisis de los Ãndices predictores de respuesta al tratamiento con Ã¡cido ursodeoxicÃ³lico en pacientes con colangitis biliar primaria. Medicina ClÃnica, 2019, 152, 377-383.	0.6	3
697	Prognosis of 732 ursodeoxycholic acidâ€treated patients with primary biliary cholangitis: A single center followâ€up study from China. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1236-1241.	2.8	15
698	Autoimmune Hepatitis and Immune-Mediated Cholestatic Liver Diseases. , 2019, , 251-305.		0
699	Primary biliary cholangitis in patients with systemic sclerosis: Unmasking the true face of Reynold's syndrome. Egyptian Rheumatologist, 2020, 42, 31-34.	1.0	2
700	Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis. Clinical Reviews in Allergy and Immunology, 2020, 58, 25-38.	6.5	86
701	The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Journal of Clinical Densitometry, 2020, 23, 223-236.	1.2	8
702	Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. Digestive Diseases and Sciences, 2020, 65, 416-422.	2.3	6

#	Article	IF	Citations
703	Rosiglitazone alleviates intrahepatic cholestasis induced by Î±â€naphthylisothiocyanate in mice: The role of circulating 15â€deoxyâ€Î”^{12,14}â€PGJ₂ and Nogo. British Journal of Pharmacology, 2020, 177, 1041-1060.	5.4	16
704	Increasing prevalence of primary biliary cholangitis in Victoria, Australia. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 673-679.	2.8	10
705	Thigh muscle MRI findings in myopathy associated with antiâ€mitochondrial antibody. Muscle and Nerve, 2020, 61, 81-87.	2.2	13
706	Treatment of SjÃ¶gren's syndrome internal organ manifestations and constitutional symptoms. , 2020, , 211-234.		0
707	Clinical utility of FibroScan as a nonâ€invasive diagnostic test for primary biliary cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1208-1214.	2.8	17
708	Evaluation of the United Kingdomâ€primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population. JGH Open, 2020, 4, 132-139.	1.6	3
709	Changes in the distribution of etiologies of cirrhosis among patients referred for liver transplantation over 11 years in Iran. European Journal of Gastroenterology and Hepatology, 2020, 32, 844-850.	1.6	5
710	Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation. Nutrition in Clinical Practice, 2020, 35, 50-62.	2.4	43
711	Increased p16INK4a-expressing senescent bile ductular cells are associated with inadequate response to ursodeoxycholic acid in primary biliary cholangitis. Journal of Autoimmunity, 2020, 107, 102377.	6.5	16
712	Chronic Liver Disease in the Obstetric Patient. Clinical Obstetrics and Gynecology, 2020, 63, 193-210.	1.1	1
713	Concomitant systemic lupus erythematosus might have a negative impact on the biochemical responses to treatment in patients with primary biliary cholangitis. Clinical Rheumatology, 2020, 39, 795-803.	2.2	7
714	Consensus guidelines: best practices for detection, assessment and management of suspected acute drugâ€induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 90-109.	3.7	21
715	Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165958.	3.8	9
716	An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance. Expert Review of Gastroenterology and Hepatology, 2020, 14, 985-998.	3.0	3
717	Laboratory diagnosis of liver disease. , 2020, , 545-559.		0
718	Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine. Medicine (United States), 2020, 99, e23107.	1.0	0
719	Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features. Digestive Diseases, 2021, 39, 366-374.	1.9	7
720	Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis. BioMed Research International, 2020, 2020, 1-11.	1.9	2

#	Article	IF	Citations
721	Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2021, 66, 2439-2451.	2.3	23
722	Characteristics of serum chemokine profile in primary biliary cholangitis. Cytokine, 2020, 136, 155291.	3.2	5
723	Changed Profile of Serum Transferrin Isoforms in Primary Biliary Cholangitis. Journal of Clinical Medicine, 2020, 9, 2894.	2.4	3
724	Do hepatic artery infusion pumps cause recurrent pleural effusions?. Journal of Surgical Case Reports, 2020, 2020, rjaa137.	0.4	1
725	Association between serum ficolin-1 level and disease progression in primary biliary cholangitis. PLoS ONE, 2020, 15, e0238300.	2.5	3
726	Replication study and meta-analysis indicate a suggestive association of RUNX3 locus with primary biliary cholangitis. Immunogenetics, 2020, 72, 467-474.	2.4	0
727	Profiling of the pattern of the human TRB/IGHâ€“CDR3 repertoire in primary biliary cholangitis patients. International Immunopharmacology, 2020, 83, 106393.	3.8	2
728	PSC and Overlap Syndromes. Current Hepatology Reports, 2020, 19, 106-118.	0.9	2
729	Role of cell autophagy in the generation of IgM and hepatic fibrosis in primary biliary cholangitis. Clinical Rheumatology, 2020, 39, 3499-3506.	2.2	6
730	Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target. Hepatology, 2020, 72, 1838-1850.	7.3	13
731	Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. Diseases (Basel, Switzerland), 2020, 8, 20.	2.5	14
732	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. Liver International, 2020, 40, 1121-1129.	3.9	15
733	Therapeutic Effects of Apamin as a Bee Venom Component for Non-Neoplastic Disease. Toxins, 2020, 12, 195.	3.4	41
734	Changes in the gut microbiota of mice orally exposed to methylimidazolium ionic liquids. PLoS ONE, 2020, 15, e0229745.	2.5	12
735	Cancer and Scleroderma. Rheumatic Disease Clinics of North America, 2020, 46, 551-564.	1.9	14
736	Implication of Increased Serum IL-31 for Primary Biliary Cholangitis. Immunological Investigations, 2021, 50, 662-670.	2.0	2
737	Primary biliary cholangitis presenting as acute ischemic stroke: A rare association. Clinical Case Reports (discontinued), 2020, 8, 274-277.	0.5	0
738	Nutritional Management of Cholestasis. Clinical Liver Disease, 2020, 15, 9-12.	2.1	6

#	Article	IF	Citations
739	Recurrent Disease After Liver Transplantation. Current Hepatology Reports, 2020, 19, 54-62.	0.9	3
740	Aging-Related Molecular Pathways in Chronic Cholestatic Conditions. Frontiers in Medicine, 2019, 6, 332.	2.6	9
741	Emerging therapies for PBC. Journal of Gastroenterology, 2020, 55, 261-272.	5.1	15
742	Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges . Clinical and Experimental Gastroenterology, 2020, Volume 13, 17-24.	2.3	12
743	Tight Junction Proteins and the Biology of Hepatobiliary Disease. International Journal of Molecular Sciences, 2020, 21, 825.	4.1	36
744	The Enlargement of Abdominal Lymph Nodes Is a Characteristic of Autoimmune Liver Disease. Mediators of Inflammation, 2020, 2020, 1-7.	3.0	4
745	Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 874-884.	1.5	5
746	Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2021, 19, 573-579.e1.	4.4	45
747	How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients with Primary Biliary Cholangitis?. Digestion, 2021, 102, 428-436.	2.3	1
748	Clinical characteristics and prognosis of concomitant systemic lupus erythematosus and primary biliary cholangitis. Clinical Rheumatology, 2021, 40, 1819-1826.	2.2	5
749	Investigational drugs in early phase development for primary biliary cholangitis. Expert Opinion on Investigational Drugs, 2021, 30, 131-141.	4.1	7
750	The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. Hepatology Research, 2021, 51, 31-38.	3.4	5
751	Decreased infiltration of CD4+ Th1 cells indicates a good response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis. Pathology Research and Practice, 2021, 217, 153291.	2.3	10
752	Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. JHEP Reports, 2021, 3, 100202.	4.9	22
753	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. Journal of Hepatology, 2021, 74, 321-329.	3.7	55
754	Cholestatic liver disease: Practice guidelines from the Saudi Association for the Study of Liver diseases and Transplantation. Saudi Journal of Gastroenterology, 2021, 27, 1.	1.1	3
755	Current understanding of primary biliary cholangitis. Clinical and Molecular Hepatology, 2021, 27, 1-21.	8.9	63
756	Transplant and Autoimmune Diseases. , 2021, , 281-293.		0

#	Article	IF	Citations
757	Platelet activation and hypercoagulability in patients with early primary biliary cholangitis compared with healthy controls. Annals of Gastroenterology, 2021, 34, 229-234.	0.6	2
758	Fibrosis and hepatic regeneration mechanism. Translational Gastroenterology and Hepatology, 2022, 7, 9-9.	3.0	8
759	Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases. World Journal of Gastroenterology, 2021, 27, 80-91.	3.3	5
760	Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-7.	1.9	3
761	The clinical and laboratory features associated with cancer in patients with primary biliary cholangitis: a longitudinal surveyâ€“based study. Clinical Rheumatology, 2021, 40, 3311-3317.	2.2	1
762	Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-10.	1.9	8
763	The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease. BioMed Research International, 2021, 2021, 1-10.	1.9	6
764	Real-World Clinical Management of Patients with Primary Biliary Cholangitisâ€”A Retrospective Multicenter Study from Germany. Journal of Clinical Medicine, 2021, 10, 1061.	2.4	11
765	Investigation of immune complexes formed by mitochondrial antigens containing a new lipoylated site in sera of primary biliary cholangitis patients. Clinical and Experimental Immunology, 2021, 204, 335-343.	2.6	2
766	Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	1
767	Expanded circulating peripheral helper T cells in primary biliary cholangitis. Molecular Immunology, 2021, 131, 44-50.	2.2	6
768	Pruritus in autoimmune connective tissue diseases. Annals of Translational Medicine, 2021, 9, 441-441.	1.7	5
769	Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. Hepatology International, 2021, 15, 437-443.	4.2	3
770	Primary biliary cholangitis. Vestnik Transplantologii I Iskusstvennykh Organov, 2021, 23, 162-170.	0.4	0
771	TheÂAsian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatology International, 2021, 15, 223-257.	4.2	37
772	Early arthritis and digestive diseases. A rheumatologistâ€™s view. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 186-193.	0.4	0
773	Male Sex Is Associated With Higher Rates of Liverâ€Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology, 2021, 74, 879-891.	7.3	36
774	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. American Journal of Gastroenterology, 2021, 116, 1514-1522.	0.4	14

#	Article	IF	Citations
775	Fibrotic Events in the Progression of Cholestatic Liver Disease. Cells, 2021, 10, 1107.	4.1	24
776	Novel HLA-DRB1 alleles contribute risk for disease susceptibility in primary biliary cholangitis. Digestive and Liver Disease, 2021, , .	0.9	2
777	Autoimmune liver damage in patients with primary Sjogren's syndrome associated with anticentromeric antibodies. Sovremennaya Revmatologiya, 2021, 15, 27-34.	0.5	0
778	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74, 1344-1354.	3.7	77
779	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. JHEP Reports, 2021, 3, 100276.	4.9	5
780	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	1.3	27
781	Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. Drugs, 2021, 81, 1181-1192.	10.9	37
782	Dynamin-related protein 1 deficiency accelerates lipopolysaccharide-induced acute liver injury and inflammation in mice. Communications Biology, 2021, 4, 894.	4.4	9
783	5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance. International Immunopharmacology, 2021, 96, 107820.	3.8	8
785	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY BILIARY CHOLANGITIS. Clinics and Research in Hepatology and Gastroenterology, 2021, 46, 101770.	1.5	4
786	Primary biliary cirrhosis in early childhood â€“ A rare case report. International Journal of Surgery Case Reports, 2021, 85, 106215.	0.6	1
787	Downregulation of Programmed Death-1 Pathway Promoting CD8â€‰+â€‰T Cell Cytotoxicity in Primary Biliary Cholangitis. Digestive Diseases and Sciences, 2022, 67, 2981-2993.	2.3	3
788	Liver Zonation â€“ Revisiting Old Questions With New Technologies. Frontiers in Physiology, 2021, 12, 732929.	2.8	75
789	Glycan biomarkers of autoimmunity and bile acid-associated alterations of the human glycome: Primary biliary cirrhosis and primary sclerosing cholangitis-specific glycans. Clinical Immunology, 2021, 230, 108825.	3.2	2
790	Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5Âyears of follow up. Alimentary Pharmacology and Therapeutics, 2021, 54, 1202-1212.	3.7	15
791	The Role of B Cells in Adult and Paediatric Liver Injury. Frontiers in Immunology, 2021, 12, 729143.	4.8	17
792	Ursodeoxycholic Acid at 18â€“22â€‰mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-7.	1.9	4
793	The significance of cytoplasmic antinuclear antibody patterns in autoimmune liver disease. PLoS ONE, 2021, 16, e0244950.	2.5	5

#	Article	IF	Citations
794	Baricitinib and primary biliary cholangitis. Journal of Translational Autoimmunity, 2021, 4, 100107.	4.0	13
796	Biliary and Vascular Changes. , 2016, , 37-69.		1
797	Primary Biliary Cholangitis. , 2019, , 221-235.		1
798	Genetic Factors in the Pathogenesis of Primary Biliary Cirrhosis. , 2014, , 157-169.		1
799	Validation of the Expanded Baveno-VI Criteria for Screening Gastroscopy in Asian Patients with Compensated Advanced Chronic Liver Disease. Digestive Diseases and Sciences, 2021, 66, 1343-1348.	2.3	3
801	Liver Disease. , 2012, , 1637-1693.		4
802	Proteinase-activated Receptor 1 Contributed to Up-regulation of Enkephalin in Keratinocytes of Patients with Obstructive Jaundice. Anesthesiology, 2014, 121, 127-139.	2.5	16
803	A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis. Liver International, 2020, 40, 1926-1933.	3.9	14
804	Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. BMJ Case Reports, 2017, 2017, bcr-2017-220824.	0.5	3
805	Scalar-on-function regression for predicting distal outcomes from intensively gathered longitudinal data: Interpretability for applied scientists. Statistics Surveys, 2019, 13, 150-180.	11.3	7
806	Case Report: Ursodeoxycholic acid treatment in Niemann-Pick disease type C; clinical experience in four cases. Wellcome Open Research, 2017, 2, 75.	1.8	11
807	Meta-Analysis Assessment of GP210 and SP100 for the Diagnosis of Primary Biliary Cirrhosis. PLoS ONE, 2014, 9, e101916.	2.5	40
808	The Value of MRI in the Diagnosis of Primary Biliary Cirrhosis and Assessment of Liver Fibrosis. PLoS ONE, 2015, 10, e0120110.	2.5	19
809	Low Serum Hepcidin in Patients with Autoimmune Liver Diseases. PLoS ONE, 2015, 10, e0135486.	2.5	25
810	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS ONE, 2016, 11, e0159612.	2.5	23
811	Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study. PLoS ONE, 2018, 13, e0194397.	2.5	11
812	Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective. Journal of Clinical and Translational Hepatology, 2014, 2, 266-84.	1.4	20
813	Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review. Journal of Clinical and Translational Hepatology, 2018, 6, 1-8.	1.4	11

#	Article	IF	Citations
814	Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches. Journal of Clinical and Translational Hepatology, 2020, X, 1-12.	1.4	28
815	Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1499-1507.	2.3	15
816	Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Revista Espanola De Enfermedades Digestivas, 2018, 110, 557-563.	0.3	23
817	Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure. Oncotarget, 2015, 6, 28011-28025.	1.8	36
818	Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. Oncotarget, 2015, 6, 24533-24549.	1.8	10
819	Management of primary biliary cholangitis prior to obeticholic acid availability. Minerva Medica, 2018, 109, 410-417.	0.9	7
820	Analysis of disease-pathways by susceptibility genes in primary biliary cirrhosis. Inflammation and Regeneration, 2014, 34, 078-086.	3.7	2
821	Indirect immunofluorescence and ELISA for testing of antimitochondrial antibodies -Which is better?-. Acta Hepatologica Japonica, 2010, 51, 531-533.	0.1	2
822	Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 422 T	0.7	8
824	Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?. World Journal of Gastroenterology, 2012, 18, 4855.	3.3	11
825	Liver diseases in pregnancy: Diseases not unique to pregnancy. World Journal of Gastroenterology, 2013, 19, 7630.	3.3	17
826	Study of liver cirrhosis over ten consecutive years in Southern China. World Journal of Gastroenterology, 2014, 20, 13546.	3.3	47
827	Autoantibodies in Chinese patients with chronic hepatitis B: Prevalence and clinical associations. World Journal of Gastroenterology, 2015, 21, 283.	3.3	18
828	Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation. World Journal of Gastroenterology, 2015, 21, 2236-2241.	3.3	6
829	Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. World Journal of Gastroenterology, 2016, 22, 7579.	3.3	12
830	Recent advances in the management of pruritus in chronic liver diseases. World Journal of Gastroenterology, 2017, 23, 3418.	3.3	34
831	Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases. World Journal of Gastroenterology, 2017, 23, 4839.	3.3	22
832	Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis. World Journal of Gastroenterology, 2017, 23, 7191-7197.	3.3	6

#	Article	IF	Citations
833	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. World Journal of Gastroenterology, 2017, 23, 7863-7874.	3.3	7
834	Osteoporosis in primary biliary cholangitis. World Journal of Gastroenterology, 2018, 24, 3513-3520.	3.3	29
835	Management of Primary Biliary Cirrhosis. Korean Journal of Medicine, 2012, 82, 32.	0.3	12
836	Autoimmune liver disease and the enteric microbiome. AIMS Microbiology, 2018, 4, 334-346.	2.2	3
837	Recent advances in the development of farnesoid X receptor agonists. Annals of Translational Medicine, 2015, 3, 5.	1.7	115
838	Overlapping of Primary Biliary Cirrhosis and Small Duct Primary Sclerosing Cholangitis: First Case Report. Journal of Clinical Medicine Research, 2012, 4, 429-33.	1.2	20
839	Cutoff values of acoustic radiation force impulse two-location measurements in different etiologies of liver fibrosis. Journal of Medical Ultrasound, 2019, 27, 130.	0.4	4
840	Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome. World Journal of Hepatology, 2013, 5, 577.	2.0	17
841	Primary biliary cirrhosis: From bench to bedside. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2015, 6, 32.	1.1	11
842	Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. Hepatitis Monthly, 2016, 16, e31681.	0.2	4
843	Rates of decompensation, hepatocellular carcinoma and mortality in AMAâ€negative primary biliary cholangitis cirrhosis. Liver International, 2022, 42, 384-393.	3.9	7
844	Primary Biliary Cholangitis. , 2022, , 27-84.		0
845	Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis. Scientific Reports, 2021, 11, 19705.	3.3	8
846	Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases. Cells, 2021, 10, 2772.	4.1	4
847	Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2021, 78, 227-234.	0.4	9
850	Nonneoplastic Hepatobiliary Disease. , 2011, , 1771-1827.		0
851	Cholestasis and Biliary Tract Disorders. , 2011, , 52-70.		1
852	Prolonged treatment with ursodeoxycholic acid of patients with primary biliary cirrhosis and their clinical course -Study Group for Urso-PBC Special Survey-. Acta Hepatologica Japonica, 2011, 52, 584-601.	0.1	0

#	Article	IF	Citations
853	Managing the Patient with Features of Overlapping Autoimmune Liver Disease. , 2012, , 217-234.		0
855	Primary biliary cirrhosis and liver transplantation. Intractable and Rare Diseases Research, 2012, 1, 66-80.	0.9	10
860	Inflammatory hepatobiliary diseases. , 2013, , 910-921.		0
862	The Clinical Significance of Simplified Scoring Criteria as a Diagnostic Tool for Overlap Syndrome in Korea. Korean Journal of Medicine, 2013, 84, 211.	0.3	2
863	The Diagnosis and Classification of Immune-Mediated Biliary Diseases. , 2014, , 111-122.		0
865	Overlap Syndromes. , 2014, , 317-329.		0
866	Complications of Cholestasis. Clinical Gastroenterology, 2014, , 163-188.	0.0	0
867	Diagnosis and UDCA Treatment of Primary Biliary Cirrhosis. , 2014, , 249-259.		0
868	Management of the Patients with Feature of Autoimmune Hepatitis. , 2014, , 277-286.		0
869	HepatopatÃas autoinmunes: cirrosis biliar primaria, hepatitis autoinmune y colangitis esclerosante primaria. , 2014, , 50-55.		1
872	A case of hepatitis hard to diagnose autoimmune hepatitis or primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Acta Hepatologica Japonica, 2014, 55, 360-366.	0.1	0
873	Liver Transplantation for Primary Biliary Cirrhosis. , 2014, , 287-300.		3
874	Optimal use of corticosteroids in gastroenterology and hepatology. Journal of Translational Internal Medicine, 2014, 2, 53-58.	2.5	2
875	PRIMARY BILIARY CIRRHOSIS ASSOCIATION WITH RHEUMATOID ARTHRITIS: A RARE CASE PRESENTATION. Journal of Evolution of Medical and Dental Sciences, 2014, 3, 10117-10119.	0.1	0
876	A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature. Euroasian Journal of Hepato-gastroenterology, 2015, 5, 122-126.	0.5	1
878	Hepatobiliary Diseases. , 2016, , 253-266.		0
879	Cholestasis. Clinical Gastroenterology, 2016, , 141-142.	0.0	0
880	Primary Biliary Cholangitis in a Man. MOJ Clinical & Medical Case Reports, 2016, 4, .	0.0	0

#	Article	IF	Citations
881	Cancer in Systemic Sclerosis. , 2017, , 525-532.		0
882	Overlap Syndromes of Primary Sclerosing Cholangitis. , 2017, , 41-57.		0
883	Primary Biliary Cholangitis. In Clinical Practice, 2017, , 227-242.	0.0	0
884	Health Maintenance in Liver Disease and Cirrhosis. , 2017, , 89-98.		1
885	Autoimmune Liver Diseases: Primary Biliary Cholangitis. , 2017, , 251-287.		0
886	Autoimmune Liver Diseases: Overlap Syndromes. , 2017, , 307-328.		0
887	A Case of Primary Biliary Cirrhosis Mimicking Acute Hepatitis B in the Clinic, Republic of Korea. Korean Journal of Family Medicine, 2017, 38, 43.	1.2	0
888	Bile Acids and Cholestatic Liver Disease 1: Primary Biliary Cholangitis (PBC). , 2017, , 109-119.		0
889	Haut. , 2018, , 869-900.		0
890	Role of Nerve Growth Factor (NGF) and Its Receptor Tyrosine Kinase A (TrK A) in Egyptian Cirrhotic Patients with Pruritus. Open Journal of Gastroenterology, 2018, 08, 317-326.	0.1	0
891	Racial disparity in primary biliary cholangitis (pbc) patients seen in an urban academic gi clinic. Gastroenterology & Hepatology (Bartlesville, Okla), 2018, 9, .	0.1	0
892	Risk stratification and treatment of primary biliary cholangitis. Revista Espanola De Enfermedades Digestivas, 2018, 111, 63-70.	0.3	1
893	Primary Biliary Cholangitis. , 2018, , 610-625.e3.		0
894	An adult case of primary biliary cholangitis accompanied by a patent ductus venosus showing type-I congenital absence of the portal vein. Acta Hepatologica Japonica, 2018, 59, 217-223.	0.1	0
895	Wouldn't Human Understanding be Necessary to Treat Patients with Pancreaticobiliary Disease More Effectively?. The Korean Journal of Pancreas and Biliary Tract, 2018, 23, 89-100.	0.1	0
897	Primary Biliary Cirrhosis and Ankylosing Spondylitis, A Rare Association. Medicina Interna (Bucharest,) Tj ETQq1 1 0.784314 rgBT /Ove	0.0	1
898	Role of regulatory T cells in pathogenesis and therapy of autoimmune liver disease. World Chinese Journal of Digestology, 2019, 27, 665-670.	0.1	0
899	The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis. Annals of Translational Medicine, 2019, 7, 389-389.	1.7	7

#	Article	IF	Citations
900	Â«GastroenterologicalÂ» rheumatology: differential diagnosis of early arthritis. Sovremennaya Revmatologiya, 2019, 13, 76-81.	0.5	1
901	Seronegative Primary Biliary Cholangitis in a Middle Age Male- A Rare Entity. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 883-886.	0.0	0
902	Autoimmune Overlap Syndromes. , 2020, , 137-149.		0
903	Prospects of using biotechnology to improve morphofunctional state of liver. IOP Conference Series: Earth and Environmental Science, 0, 613, 012050.	0.3	0
904	Primary Biliary Cholangitis. , 2020, , 335-357.		1
905	Assessment of Liver Function. , 2020, , 407-426.		0
907	Diffuse Systemic Sclerosis in a Patient with Primary Biliary Cirrhosis and Autoimmune Hepatitis Overlap Syndrome: A Case Report. Annals of Dermatology, 2020, 32, 69.	0.9	0
908	Primary Biliary Cholangitis. , 2020, , 1149-1171.		1
909	Colestasis en el adulto: enfoque diagnÃ³stico y terapÃ©utico. RevisiÃ³n de tema. Revista Colombiana De Gastroenterologia, 2020, 35, 76-86.	0.2	1
910	Early histopathologic changes in primary biliary cholangitis: does â€˜minimal changeâ€™ primary biliary cholangitis exist? A pathologistâ€™s view. European Journal of Gastroenterology and Hepatology, 2021, 33, e7-e12.	1.6	3
911	Primary biliary cholangitis: review for radiologists. Abdominal Radiology, 2023, 48, 127-135.	2.1	6
912	Non-tumoral Pathology of the Intrahepatic Biliary Tract. Medical Radiology, 2021, , 337-364.	0.1	0
913	OtoimmÃ¼n karaciÄŸer hastalÄ±ÄŸÄ±nda oksidatif dengesizlik: oksidan-antioksidan durumun ve iskemi modifiye albÃ¼minin deÄŸerlendirilmesi. SÃ¼leyman Demirel Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.2	0
914	Keratin 19 and mesenchymal markers for evaluation of epithelialâ€“mesenchymal transition and stem cell niche components in primary biliary cholangitis by sequential elution-stripping multiplex immunohistochemistry. Journal of Histotechnology, 2020, 43, 163-173.	0.5	3
915	Clinical significance of IgG antimitochondrialÂM2 antibody levels in primary biliary cholangitis: A single center study from China. PLoS ONE, 2020, 15, e0242164.	2.5	2
917	Management of pruritus in patients with cholestatic liver disease. Gastroenterology and Hepatology, 2011, 7, 615-7.	0.1	6
918	A study of aetiology of portal hypertension in adults (including the elderly) at a tertiary centre in southern India. Indian Journal of Medical Research, 2013, 137, 922-7.	1.0	18
919	Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. Gastroenterology and Hepatology, 2018, 14, 154-163.	0.1	7

#	Article	IF	Citations
920	Liver biopsy diagnosis of hepatitis: clues to clinically-meaningful reporting. Missouri Medicine, 2010, 107, 113-8.	0.3	4
921	Use of Obeticholic Acid in Patients With Primary Biliary Cholangitis. Gastroenterology and Hepatology, 2018, 14, 654-657.	0.1	2
922	Primary biliary cholangitis with contemporary presence of anti-mithocondrial and anti-rods and rings autoantibodies: literature first case. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, 76-82.	0.6	5
923	Evaluation of the effects of additional therapy with oxymel in patients with refractory primary sclerosing cholangitis and primary biliary cholangitis: A quasi-experimental study. Avicenna Journal of Phytomedicine, 2021, 11, 154-167.	0.2	0
925	The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China. Digestive and Liver Disease, 2022, 54, 1094-1100.	0.9	4
926	QTc interval prolongation in the patients with primary biliary cholangitis. Annals of Noninvasive Electrocardiology, 2022, 27, e12925.	1.1	3
927	Approach to the patient with cholestasis and jaundice syndrome. Joint AMH, AMG, and AMEG scientific position statement. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2021, 87, 80-80.	0.2	0
928	Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis. Minerva Medica, 2023, 113, .	0.9	11
929	New agents for immunosuppression. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2021, 54-55, 101763.	2.4	2
930	Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis. Disease Markers, 2022, 2022, 1-7.	1.3	3
931	Characterization of the Pathology, Biochemistry, and Immune Response in Kunming (KM) Mice Following Fasciola gigantica Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 793571.	3.9	4
932	Synthesis and Anti-Hepatoma Activities of U12 Derivatives Arresting G0/G1 Phase and Inducing Apoptosis by PI3K/AKT/mTOR Pathway. Pharmaceuticals, 2022, 15, 107.	3.8	3
933	The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment. Current Opinion in Gastroenterology, 2022, 38, 136-143.	2.3	5
934	Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Journal of Clinical Medicine, 2022, 11, 681.	2.4	0
935	Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases. Journal of Translational Autoimmunity, 2022, 5, 100145.	4.0	16
936	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatology International, 2022, 16, 1-23.	4.2	45
937	Etiological features of cirrhosis inpatients in Beijing, China. Chinese Medical Journal, 2013, 126, 2430-2434.	2.3	3
939	Haut. , 2022, , 961-996.		0

#	Article	IF	Citations
940	Autoimmunity overlaps primary biliary cirrhosis: a not straightforward diagnosis. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2022, 68, 139-141.	0.7	0
941	Antigen Reactivity and Clinical Significance of Autoantibodies Directed Against the Pyruvate Dehydrogenase Antigen Complex in Patients With Connective Tissue Disease. Frontiers in Immunology, 2022, 13, 822996.	4.8	5
942	Immunoglobulin M: A Neglected Serum Biomarker in Treatmentâ€Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase. Hepatology Communications, 2022, 6, 1403-1412.	4.3	3
943	The Role of Autoantibody Testing in Modern Personalized Medicine. Clinical Reviews in Allergy and Immunology, 2022, 63, 251-288.	6.5	3
944	Pregnancy in women with liver cirrhosis is associated with increased risk for complications: A systematic review and metaâ€analysis of the literature. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1644-1652.	2.3	7
945	Effect of LncRNA XIST on Immune Cells of Primary Biliary Cholangitis. Frontiers in Immunology, 2022, 13, 816433.	4.8	6
946	The latest research trends in primary biliary cholangitis: a bibliometric analysis. Clinical and Experimental Medicine, 2023, 23, 347-355.	3.6	2
947	Naturally-derived endoplasmic reticulum stress inhibitors for osteoarthritis?. European Journal of Pharmacology, 2022, 922, 174903.	3.5	8
948	Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium. European Journal of Gastroenterology and Hepatology, 2021, 33, e197-e205.	1.6	4
950	The NOD Mouse Beyond Autoimmune Diabetes. Frontiers in Immunology, 2022, 13, 874769.	4.8	20
951	Disease Monitoring Parameters for Autoimmune Diseases. Asian Pacific Journal of Health Sciences, 2021, 8, 24-31.	0.1	1
953	Primary Biliary Cholangitis with Ankylosing Spondylitis. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2022, 79, 270-273.	0.4	1
954	Clinical Patterns of Primary Biliary Cholangitis: Comparison Between Two European Case Series. Reviews on Recent Clinical Trials, 2022, 17, 136-142.	0.8	1
955	Mechanism for development of malnutrition in primary biliary cholangitis. World Journal of Meta-analysis, 2022, 10, 81-98.	0.1	4
956	Network Proximity-Based Drug Repurposing Strategy for Early and Late Stages of Primary Biliary Cholangitis. Biomedicines, 2022, 10, 1694.	3.2	2
957	PPARÎ±: A potential therapeutic target of cholestasis. Frontiers in Pharmacology, 0, 13, .	3.5	8
959	Potential mesenchymal stem cell therapeutics for treating primary biliary cholangitis: advances, challenges, and perspectives. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	2
960	Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments. American Journal of Clinical Dermatology, 2022, 23, 647-659.	6.7	11

#	Article	IF	Citations
961	Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis. BMJ Open Gastroenterology, 2022, 9, e000857.	2.7	1
962	Macrophage polarization is involved in liver fibrosis induced by β₁-adrenoceptor autoantibody. Acta Biochimica Et Biophysica Sinica, 2022, 54, 1100-1112.	2.0	2
963	Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China. World Journal of Gastroenterology, 2022, 28, 4417-4430.	3.3	2
964	Circulating extracellular vesicleâ€encapsulated microRNAâ€557 induces a proinflammatory immune response and serves as a diagnostic or relapse marker in autoimmune hepatitis. Hepatology Research, 2022, 52, 1034-1049.	3.4	3
965	Primary biliary cholangitis presenting with Fanconi syndrome: an important phenotype. BMJ Case Reports, 2022, 15, e248461.	0.5	1
966	A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. European Journal of Medicinal Chemistry, 2022, 243, 114742.	5.5	1
967	A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211141.	2.5	7
968	Nicht-alkoholische Fettlebererkrankung als KomorbiditÃt chronischer Lebererkrankungen. , 2022, , 301-309.		0
969	The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism. Frontiers in Immunology, 0, 13, .	4.8	3
970	LLM-PBC: Logic Learning Machine-Based Explainable Rules Accurately Stratify the Genetic Risk of Primary Biliary Cholangitis. Journal of Personalized Medicine, 2022, 12, 1587.	2.5	3
971	The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications. Journal of Biomedical Science, 2022, 29, .	7.0	7
974	Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatology Communications, 2022, 6, 3487-3495.	4.3	8
975	Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 26-36.	17.8	16
976	Transient positive antimitochondrial M2 in sera of patients with connective tissue diseases after intravenous immunoglobulin infusions. Rheumatology & Autoimmunity, 0, , .	0.8	0
977	Advances in understanding the regulatory mechanism of organic solute transporter Î±-Î². Life Sciences, 2022, 310, 121109.	4.3	3
978	Ursodeoxycholic acid use in lactating female patients is associated with clinically negligible concentrations of this bile acid in breast milk. Scientific Reports, 2022, 12, .	3.3	1
979	Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital. Journal of Clinical and Experimental Hepatology, 2023, 13, 241-251.	0.9	3
980	Pathologic features and differential diagnosis of chronic hepatitis. Diagnostic Histopathology, 2023, 29, 12-22.	0.4	1

#	Article	IF	Citations
981	Current trends and future perspectives in the treatment of PBC and PSC: A review. Health Sciences Review, 2022, , 100065.	1.5	0
982	Diagnostic value
of screening methods for the determination of antinuclear antibodies using indirect immunofluorescence on HEp-2 cells and
enzyme immunoassay in autoimmune liver diseases. Klinicheskeskaya Laboratornaya Diagnostika, 2022, 67, 652-657.	0.5	0
983	Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis. Biomedicines, 2022, 10, 3046.	3.2	5
984	Automated Machine Learning in Predicting 30-Day Mortality in Patients with Non-Cholestatic Cirrhosis. Journal of Personalized Medicine, 2022, 12, 1930.	2.5	2
985	Pathogenesis and Treatment of Pruritus Associated with Chronic Kidney Disease and Cholestasis. International Journal of Molecular Sciences, 2023, 24, 1559.	4.1	4
986	An Assessment of the Serum Activity of ADH and ALDH in Patients with Primary Biliary Cholangitis. Archivum Immunologiae Et Therapiae Experimentalis, 2023, 71, .	2.3	1
987	Challenges for diagnosis and treatment of primary biliary cholangitis. , 2023, , 215-241.		0
988	Murine breast cancers disorganize the liver transcriptome in a zonated manner. Communications Biology, 2023, 6, .	4.4	4
990	Non-Neoplastic Disorders of the Liver. , 2024, , 489-556.		0
991	Influence of ursodeoxycholic acid on blood glucose, insulin and GLP-1 in rats with liver fibrosis induced by bile duct ligation. Diabetology and Metabolic Syndrome, 2023, 15, .	2.7	4
992	<scp>CCL26</scp> in primary biliary cholangitis â€“ Is it a novel disease mediator?. International Journal of Rheumatic Diseases, 2023, 26, 648-656.	1.9	0
993	Immune thrombocytopenic purpura in primary biliary cholangitis and localized cutaneous systemic sclerosis: case report and literature review. Clinical Journal of Gastroenterology, 0, , .	0.8	0
994	Dyslipidemia and its features in primary biliary cholangitis. Zdravoohranenie TadÅ¾ikistana, 2023, , 119-130.	0.1	0
995	Zero Mortality in Living-Donor Liver Transplantation for Primary Biliary Cholangitis in Patients With a Meld Score of <20. Transplantation Proceedings, 2023, , .	0.6	0
996	Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets. Pulmonary Pharmacology and Therapeutics, 2023, 81, 102218.	2.6	1
997	Study of 43 <scp>SLE</scp> patients with autoimmune liver cirrhosis: emphasis on clinical features and differences from lupus without cirrhosis. International Journal of Rheumatic Diseases, 0, , .	1.9	0
998	The Albumin-Bilirubin Score as a Predictor of Liver-Related Mortality in Primary Biliary Cholangitis with Compensated Cirrhosis. Digestive Diseases, 2023, 41, 946-956.	1.9	1
999	Systemic Lupus Erythematosus combined with evans syndrome and primary Biliary Cirrhosis: A rare case report. Asian Journal of Surgery, 2023, , .	0.4	0

#	Article	IF	Citations
1000	Correlation between individual autoantibodies and clinical features in primary biliary cholangitis: results of a retrospective longitudinal study. European Journal of Gastroenterology and Hepatology, 2023, 35, 682-689.	1.6	0
1001	Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products. Frontiers in Immunology, 0, 14, .	4.8	1
1002	The role of miRNAs in the development of cholangiopathies. Part 1. ZdorovÊ¹e Rebenka, 2023, 18, 323-328.	0.2	0
1003	UDCA treatment against COVIDâ€19: Do we have enough clinical evidence for drug repurposing?. Journal of Internal Medicine, 2024, 295, 110-112.	6.0	1
1004	FcÎ³RIIB expression increases during primary biliary cholangitis. Molecular Immunology, 2023, 162, 30-37.	2.2	1
1005	Pathophysiology of biochemical signs of primary biliary cholangitis. , 0, , 149-171.		0
1006	Primary ciliumâ€mediated signaling cascade suppresses ageâ€related biliary fibrosis. Journal of Cellular Physiology, 2023, 238, 2600-2611.	4.1	3
1007	Research Progress on Risk Factors for Primary Biliary Cirrhosis. Advances in Clinical Medicine, 2023, 13, 11517-11522.	0.0	0
1008	NOTCH signalling â€“ a core regulator of bile duct disease?. DMM Disease Models and Mechanisms, 2023, 16, .	2.4	0
1009	Antimitochondrial antibody-negative primary biliary cirrhosis with secondary Sjogren syndrome: a case report. Annals of Medicine and Surgery, 2023, 85, 5645-5648.	1.1	0
1010	ChIP-seq analysis found IL21R, a target gene of GTF2Iâ€“the susceptibility gene for primary biliary cholangitis in Chinese Han. Hepatology International, 0, , .	4.2	0
1011	Histopathologic Approach to Cholestatic Diseases of the Liver. AJSP Review and Reports, 2018, 23, 199-213.	0.1	0
1012	Antimitochondrial antibody associated with liver cirrhosis in patients with primary biliary cholangitis. Medicine (United States), 2023, 102, e35617.	1.0	0
1013	Cholestasis and Biliary Tract Disorders. , 2024, , 74-100.e4.		0
1014	Curcumin and analogues in mitigating liver injury and disease consequences: From molecular mechanisms to clinical perspectives. Phytomedicine, 2024, 123, 155234.	5.3	0
1015	Osteoporosis and Chronic Liver Disease. , 2023, , 1-16.		0
1017	Mimickers of immunoglobulin G4-related hepatobiliary disease on biopsy. Seminars in Diagnostic Pathology, 2024, 41, 95-107.	1.5	0
1018	Laboratory Diagnostics in Autoimmune Diseases. , 2023, , 489-500.		0

#	Article	IF	Citations
1019	SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA. Cell Reports Medicine, 2024, 5, 101439.	6.5	0
1020	Comparative histologic features among liver biopsies with biliary-pattern injury and confirmed clinical diagnoses. Human Pathology, 2024, 146, 8-14.	2.0	0